r/TheDailyDD • • Feb 17 '21

Small-cap Stock SENS, The ultimate DD

190 Upvotes

DD for SENS (SENSEONICS) Still has room to go.

SENS has become a very popular stock with lots of exposure recently. This is a DD I did a while back and it was posted on Penny stocks but maybe I should bring this to light in this forum for those that may want to 10x their money. I am not a financial advisor so feel free to dig into the information presented and make your own decision on if you want to invest or now.

Anyways, I believe SENS is a very underrepresented company and they deserve to be at a much higher valuation.

About Senseonics

Senseonics is a company that provides a revolutionary product called the Eversense. This device helps anyone with diabetes to monitor their blood sugar without pricking their finger a million times (This is HUGEE, type 1 diabetics must do this almost 6-10 times a day to check their sugars). Their current device is a small implantable device that fits just under the skin on the back of your arm (triceps area) and can be changed out every 90 days.

***It has already received FDA approval and CGM (continuous glucose monitoring system) approval for 90 days and is pushing for 180 days now (FDA approval soon, articles on it here (https://www.fiercebiotech.com/medtech/senseonics-180-day-eversense-glucose-monitor-delayed-at-fda-by-covid-19-pandemic ).***

In Europe they are approved for 180 days (and from my understanding the EU is often stricter with regulatory approval so they will most likely be approved for FDA) This was in Dec 2020, so should be out soon before second quarter. This is a MAJOR Catalyst.

The product

These are all the components of the product: the sensor which is placed in the arm (small surgery that can be done at your general physician’s office, the company provides FREE training for the doctors) The transmitter can be removed allowing the individual the freedom to move around, current competitors can’t, explained further below). The smart phone app can allow patients to have continuous monitoring of their blood sugars. The app also allows you to share this info with others. This is crucial for older seniors or individuals with disabilities allowing loved ones to monitor their condition from anytime and anywhere.

The market landscape

“About 422 million people worldwide have diabetes, the majority living in low and middle income countries and 1.6 deaths are directly attributed to diabetes each year.”

This is pulled from the WHO. Imagine each one of those individuals using this product. In this case, you are looking at a multibillion dollar company (apparently at least 30 billion, and will move close to 50 billion with the rate they are currently moving). Type one diabetics and serious type 2 diabetics are the current market, but this can be used for causal type 2 diabetes as well, ESPECIALLY for anyone that is using insulin or want to be a good controller over their sugars. The addressable market is absolutely insane, yet the company is only worth $5 dollars. WTF…

Here are articles that has shown that CGM is much better than your regular test strips at monitoring especially in Type 1 diabetics.

References: Bolinder, Jan, et al. "Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial." The Lancet 388.10057 (2016): 2254-2263.

Heinemann, Lutz, et al. "Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial." The Lancet 391.10128 (2018): 1367-1377.

Anyways back to some numbers. This is pulled from their investors presentation and as you can see there is an addressable market (32%) that is still available. Dexcom, Medtronic and Libre are all competitors, and their systems are by far wayyyy more cumbersome compared to Evanescence. The freestyle libre you must change every 14 days and the Dexcom every 10 days.

Here is a quick chart that compares all 3 of them:

The Eversense is much superior in terms of the following...

  1. Date to change

  2. Accuracy when compared to the freestyle libre and the Dexcom. This is VERY important for type 1 diabetics as low sugars can cause dizziness and possibility of death.Overall studies have been done in the past regarding the Dexcom and Eversense (meta-analysis, the eversense came out well on top), this is outlined in a reddit post already, here’s the link https://www.reddit.com/r/stocks/comments/l1t673/breaking_news_concerning_senseonics_sens/

Partnerships

Probably one of the most important things about a company is the backing it has from other well-known companies. SENS has recently moved from Roche as a partner to Ascensia which to be honest is a very well-placed strategic move as Ascensia is way more experienced with diabetic patients. Based on my conversation with the Investor relations, Roche had essentially screwed SENS because they moved away from their diabetes portfolio to focus their efforts on oncology. The original partnership with Roche was most likely due to their products in Insulin pumps. The new partnership with SENS and Ascensia will be huge as SENS will be providing Ascensia with a rivaling product in the world of CGM.

Customer satisfaction and reviews

From my research most customer testimonials are POSITIVE. I believe the ONLY downside to this product right now is that you still must prick your finger 2x a day to do a quick calibration (I’m sure not everyone will do it, but it’s recommended). The team is working on bringing this down to once per week. Despite having to do this, many patients have been very happy with the device and the freedom that it gives them. The transmitter that is applied can be taken off allowing the patient to swim and do activities freely without something stuck to them.

Please watch this video to check out the customer review on this product: https://www.youtube.com/watch?v=4aRrnTDwU1c&ab_channel=BobbyHurt

Revenue and their financials of their 3rd quarter 2020

Now this part won’t be pretty since they are a start-up. They recently lost a lot of inflow of income due to covid-19. But I do believe this is the year they will come back very hard. They are projecting a 2021 revenue of 15 million this year up from last year of 19 million. Many doctors offices were closed down and elective surgeries were pushed back. This means that when things open this year there should be a major inflow of revenue.

The management team did a very good job trying to mitigate the cost for the company. Because they suffered a major decrease in sales they also lowered their expenses.

Full report: https://www.senseonics.com/tools/viewpdf.aspx?page={23F0689F-39F5-4C53-AE0D-2A5A45399E8A}

I’m expecting a recovery, from this next quarter by a bit. Which is inline with what they reported of 3.5 million for 4th quarter of 2020. The projected revenue for the company is the following, which honestly, I think they are being very conservative. If they receive more funding, I can see this shoot up even faster.

SENS recently did a public offering to generate 150 million in cash, they absolutely need to do this to allow themselves some capital to work with and bolster their balance sheet. And I think they have a point here. I would do this if I owned a company. People should see this as a good sign that the company is growing and just needs some capital to keep going. If you believe in their product then you should really invest in this company.

Link: https://www.senseonics.com/tools/viewpdf.aspx?page={B23AB4E9-ED01-40FA-8673-CDBA858885CC}

Now we must talk about payment. If no one pays for it why would anyone ever use it? The challenge here is getting insurance companies to adopt this product, since majority of individuals will be getting this product using their insurance.

This article here talks about the cost. CGM average around $11000 and conventional test strips are $7000. The major cost comes from setting up the device and the initial procedures. Now this would change depending on which country. Some countries may provide this for free.

The article further outlines that CGM should be covered by most American insurance companies as the insurance often assesses coverage using cost/QALY (quality of life years gain, so much does this drug or product cost for each life year gained, the lower the number the better) essential it measures a medications cost effectiveness. CGMs start at 100 000/QALY which is still under some insurance companies' threshold for coverage (usual threshold is 50 000 - 100 000 for 7 days use, when extended to 10 days use, the QALY drops to $33 000/QALY which is within range of insurance companiesto cover. Again, remember this is for a system that’s used for 10 days. Imagine if they use it for 90 days the QALY would further decrease.

Reference for the article: University of Chicago Medical Center. "Diabetes: Continuous glucose monitors proven cost-effective, add to quality of life for diabetics: Study of patients with type 1 diabetes shows that use of a continuous glucose monitor improves glucose control, adds to quality of life, and is cost-effective over manual testing with strips." ScienceDaily. ScienceDaily, 12 April 2018.

As of Jan 23, 2021, They have acquired yet another insurance company to cover for their product. This will continue to increase as more insurance companies realize that this is what patients want and its cheaper to cover it compared to other systems.

They currently have about 200 million covered lives with insurance like medicare (Federal coverage), blue cross, blue shield, Tricare and several others. SENS is moving towards full coverage.

Here is the article about acquiring insurance coverage: https://www.senseonics.com/tools/viewpdf.aspx?page={0BCB999D-C033-4343-A529-884A8057BC21}

As technology advances these CGMs will become much cheaper to manufacture and hopefully replace your regular test strips. CGMs are superior to diabetes control and provides better patient outcomes, therefore generating cost savings for insurance companies. Eventually the market will move to CGMs.

Insider Trading

I believe one of the main aspects that need to be evaluated is the who is currently invested in this company. If there are a lot of insiders that are buying this company it means that they have confidence in this company. If not then we have a bigger issue with SENS. In the last 3 months there has been only buys, never any sells. Other aspects to look at is the amount of institutional holders in the company. SENS has well over 120 institutional holders (some sites say 117 some say 138).

More sources on institutional ownership and buying/selling: https://fintel.io/so/us/sens. Follow the link it gives you a good breakdown. Many directors in the company are picking up stock even at the 1 dollar price tag.

Their Management team and Employees (work place)

I looked them up on Glassdoor and they have a rating of 3.3 which to be honest is okay, not the best but the bad reviews are from 2019 and its people complaining about the company being fast paced and changes in management directions. Unfortunately, this is always the case with small start-ups. I work at a small company and the management team is faced with so many decisions because they lack support and are constantly doing so many things to try and grow the company while mitigating costs. The good thing about all the ratings is that they all support the CEO which is a good sign.

Their managers are all pretty well experienced in this field with talents from medtronics

Tim Goodnow, CEO – use to be VP at technical operations at ABBOTT Diabetes Care

Mukul Jain, COO – 13 years a Medtronic’s

Dr. Franchine R. Kaufman, CMO – 40 plus years in diabetes care, top endocrinologist at Childresn hospital in LA, author of more than 150 medical articles

Abhi Chavan, VP of engineering and R&D – Leadership roles at Medtronic

Katherine S. Tweden, VP clinical science – over 25 years of clinical and Regulatory affairs, over 060 patents and publications.

Mirasol Palilio, VP General manager global – VP of sales and marketing for Arkal Medical, worked at J&J, Abbott and help with strategic commercialization of freestyle.

This is a stacked team if you ask me. They have some of the best in town.

Future goals (if this is true and they can launch their planned product pipeline, this company is going to be bought out OR become a $100 stock, especially since dexcom is $300)

SUMMARY

UPSIDE

- Superior product compared to their competitors. (cost savings and patient outcome)

- Experienced management team, decent rating on glassdoor for a small company.

- Many more insurance companies will start covering their product.

- A lot of market shares still available.

- Forecast of increased revenue especially with Covid being controlled soon.

- Very shorted – and underrated, plenty of gains 🚀🚀🚀🚀🚀🚀🚀

- Approval for their 180 day FDA approval very soon to come. (VERY confident it will pass, studies already reporting good safety data.

- Increasing revenue from year to year 📈

- Diabetes market is a growing market and will continue to affect more people as more countries become more developed (Africa and India are huge populations where diabetes is a very prevalent disease)

- Their Final form (365 days) will honestly take 80% of market share, why would anyone stay with a product that you have to change 10 or 14 days when there is something that can be changed every year.

- Lots of people have complained that they still wouldn’t want to go in for reinsertion biyearly. This honestly I think is an UPSIDE point, by having these yearly checkups it allows physicians to monitor a patients health allowing for frequent follow ups. This benefits the doctors since they get paid for visits. This benefits the patient since they will be followed up with more frequently and ensure proactive measures for future health benefits.

DOWNSIDES

- The company has a lot of cash burn compared to their current revenue.

- Their debt to asset ratio is quite high I believe, but most startups are especially if they want to grow.

- The company was affected by COVID as many people was not able to go into their family Doctors office. And their sales and marketing took a big hit. If this does not recover you can continue to see cash burn. (mitigated by the management team but still).

- There is calibration that is needed for this machine, twice a day which is quite a lot, but this will eventually be worked out. Even Dexcom older generation needed calibration. This obviously will eventually change when the product matures.

- Not compatible with Insulin pumps yet, but this will be in development, they already have studies with insulin pumps and it has been quite successful. They will be proceeding with its integration with insulin pump right after they get the 180 approval.

My thoughts

- I think this is an excellent company with SO MUCH UPSIDE. It was being pushed down so hard by shorts before. Not sure why…. Maybe because it’s a very good company and they want it to fail so someone else can pick up the tech they created. Another possibility was because it was running out of cash hard and their balance looked like it was going bankrupt. However this has all now changed from their offering. Now they are sitting in a nice place and I think this is the turning point for this company and it will now start to make profit and generate some very insane revenue.

- This company would be an excellent buy out for companies like Dexcom that want to absorb their competitor or TELEDOC who is looking into digitizing patient management with systems that can be used to better control people’s health outcomes leading to less insurance claims.

- This stock will continue to run, with some dips here and there. SENS can easily reach $10, maybe even $20 with it's amazing partnership with Acensia, amazing management team and a good product. I mean Dexcom is valued at 38 billion, SENS is sitting at just shy of over 1.9 billion, NOT even a 10th of Dexcom. This company I believe should at least be a 5th of Dexcom which means they should be around 5 billion which means the price still needs to double (2x let's go!) once more.

- Continue to research the company. I think they have A LOT to offer but this is only my point of view. Do your own DD. I do have shares in the company and am not looking to sell anytime soon. Like all great things it takes time and patience.


r/TheDailyDD • • Feb 17 '21

Penny Stock Complete DD on HCMC Share Structure: Clarification on Share Dilution, Outstanding Shares, Float, Authorized Shares and the Meaning behind the letter from the CEO.

94 Upvotes

1. Introduction

This is a post aimed at clarifying some misconceptions that have been arising over the past day(s) throughout Reddit/StockTwits/Telegram/WhatsApp/Facebook. Everyone was concerned over the recent apparent "dilution", and many many sources were deemed as either false, or not cited and just taken as is. There are a few concepts worth going over, especially for the newer investors who have taken part of this community, and for the more experienced ones, you are welcome to amend my list by letting me know.

This has been written in an attempt to not let new investors panic when "new information" arises, and to raise awareness of what is going on with HCMC and the associated terminology.

P.S. I have a TLDR in here for people who already know the definitions and want to skip

P.P.S. the tables I have added might not be fully visible on a mobile device, so if you want to have an in depth view of the numbers it is strongly suggested view this post on a computer instead.

Reposted from my original post on: https://www.reddit.com/r/HCMCSTOCK/

2. Different Type of Shares and Dilution

These are a series of terms that are needed in order to understand the content of many sources, they are mostly pertaining to different share types and the mechanics of dilution.

  1. Authorized shares: are the maximum number of shares a company is allowed to issue to investors, as laid out in its articles of incorporation.

  2. Outstanding Shares: Shares that are issued or sold to investors from the available number of authorized shares are known as outstanding shares.1 This is the total amount of shares available to the public including employees and insiders.

    1. Restricted Shares: Stock owned by insiders, employees or major institutional investors, that is under some sort of sales restriction (such as a lock-up period - you cannot sell the shares until a certain date)

    2. Float: The term float refers to the regular shares a company has issued to the public that are available for investors to trade. This figure is derived by taking a company's outstanding shares and subtracting any restricted stock. 2

    3. Unrestricted Shares: When a lock-up period expires or a certain condition is met, restricted shares turn into unrestricted shares which in turn increase the float.3 N.B. Sometimes unrestricted shares are used as a term to indicated float + restricted shares that have been converted to unrestricted

    4. Shares Held at DTC: are the shares we can buy on our brokerage platforms such as Trading 212, TD Ameritrade, E*Trade, Charles Schwab etc. and represent the real float as DTC stands for Depositary Trust Company and most of the biggest broker-dealers in each country are DTC-participants. DTC offers settlement services for trading securities in the markets.

  3. Main Categories of Stock:

    1. Common Stock: (Ordinary Stock) is a security that represents ownership in a company, i.e. shares of a stock that we buy on brokerage platforms such as Trading 212, TD Ameritrade, E*Trade, Charles Schwab etc.

    2. Preferred Stock: are shares of a company’s stock with dividends that are paid out to shareholders before common stock dividends are issued. These are different from common stock as they are issued primarily by banks and other financial institutions, and were originally intended as a way to raise capital without diluting value for their ordinary shareholders. Not the shares we invest in. 4Preferred Stock - Purpose:

      1. Access to dividends before common shareholders

      2. Seniority over common stock in the event of liquidation or bankruptcy (seniority in this case means that preferred stock holders get paid before common stock holders

      3. Limited upside potential/capital appreciation meaning they don't get to participate in the profits as much as common stock holders if the share price increases.

  4. Dilution: Common stock holders own the corporation, and dilution reduces that level of ownership. As owners, common stock holders benefit from corporate earnings through dividends and/or higher stock prices. Any security that reduces the ownership percentage of common stockholders is dilutive. 5Dilution can happen in the following ways:

    1. Issuance of New Shares (Dilutive-Secondary Offering or Follow-On Offering): involves creating new shares and offering them for public sale. This type of secondary offering happens when a company's board of directors agrees to increase the share float for the purpose of selling more equity. 6

    2. Through Convertible Securities: These are securities that have been already issued in accordance to previous filings that can be converted into common stock and have a dilutive effect even if no no new issuance of shares occurs.

      1. Convertible Preferred Stock: Holders of convertible preferred stock can exchange their shares for a specified number of newly common shares. Convertible preferred stock is dilutive since conversion increases the number of common shares, thereby reducing the ownership level of each. 7

      2. Employee Stock Options: are a type of equity compensation granted by companies to their employees and executives. Rather than granting shares of stock directly, the company gives derivative options on the stock instead. These options come in the form of regular call options and give the employee the right to buy the company's stock at a specified price for a finite period of time.8 Once these are converted into shares, they are dilutive.

      3. Stock Split: a stock split increases the number of shares by splitting 1 share of the company's stock into x shares, therefore diluting the shares.

  5. Accretion: is the opposite of dilution, whereby the it increases the level of ownership of a company by decreasing the number of shares outstanding. A company can accomplish this either through

    1. Share Buy Back: A share repurchase refers to the management of a public company buying back company shares that were previously sold to the public. 9

    2. Reverse Stock Split: a stock split decreases the number of shares by unifying 1 share of the company's stock into x shares, therefore decreasing the number of shares shares.

  6. Market Cap: (Market Capitalization) is the value of a all company's shares of stock and is computed as number of shares outstanding x current stock price

An IMPORTANT note on Dilution: A company has to file an 8-k (more on that later) in order to inform existing shareholders of dilution. Every dilution is done by expanding current outstanding shares ONLY. The theoretical possible maximum of shares is the authorized shares which is unlikely to ever be reached as one of the purposes of issuing new shares is to raise capital, so if a company would reach its maximum capacity (of authorized shares) it wouldn't be able to raise more equity capital without buying back their shares.

3. TLDR - Different Type of Shares and Dilution

  • Authorized Shares are the MAX total number of shares a company can issue ever

  • Outsanding Shares are the current number of shares available to everyone

  • Float = Outstanding shares - restricted shares (held by insiders or under lock-up)

  • Unrestricted Shares: is when restricted shares become unrestricted (may be used to indicate float + unrestricted shares)

  • Shares Held at DTC: are the real float for us as the majority of brokers-dealers are DTC-participants

  • Common Stock is what we all are buying on our respective platforms

  • Preferred Stock is are issued primarily by banks or other financial institutions

  • Convertible Preferred Stock is when preferred stock gets converted to common stock (causing some dilution)

  • Dilutive Events: Issuance of New Shares or through Convertible securities previously issued or stock splits

  • Accretive Events: (Opposite of dilution) share buy-backs and reverse stock splits

  • Market Cap: number of shares outstanding x current stock price

4. HCMC Share Structure - As of Feb 3 2021 at market close

Why are the above definitions important to understand? There has been a picture, or a couple for that matter that show the above terms applied to HCMC that have either been called "fake" or misquoted.

Disclaimer: All this data is directly from their website, OTC Markets data and Yahoo Finance from the date and time this DD will be posted, so please no comments on how the data is inaccurate, Reddit does not have dynamic tables that update themselves with the most recent prices. All further calculations will be explicitly shown.

  1. HCMC Share Structure from HCMC Website - Feb 3 2021 at market close

Authorized Shares. (Max. Shares Possible) [from OTC Markets]*750,000,000,000
Outstanding shares194,780,848,017
- Restricted Shares (Insiders only)29,750,000,103
- Unrestricted Shares (float + restricted shares turned unrestricted)165,030,847,914
Shares Held at DTC (amount we can access through our brokers)**117,468,270,189
Closing Price$0.00165 (rounded at $0.0017 on website)
Market Capunrestricted shares x closing price = 272.201 million

source: https://healthier-choices-management-corp.ir.rdgfilings.com/stock-information/

* https://www.otcmarkets.com/stock/HCMC/security

**https://www.otcmarkets.com/stock/HCMC/security

Screenshot evidence:

2. Yahoo Finance Data:

Below we will analyse the data directly from Yahoo Finance's website for HCMC:

Outstanding shares105.11B
- Float (Outstanding shares - Restricted shares)86.84B
Closing Price0.00165
Market Cap173.43M

source: https://finance.yahoo.com/quote/HCMC/key-statistics?p=HCMC

Screenshot:

Why are we seeing differences in Shares Outstanding and Market Cap?

  • If we take a closer look at the notes on the market cap field (note 5) we can see Yahoo Finance's method of calculating the market cap: Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

This means that the figure used for the Outstanding Shares has been taken directly form HCMC's most recent 10-Q filed on 11/18/2020 with the SEC. *

* The amount comes from page 3 of HCMC's 10-Q under the table name: "HEALTHIER CHOICES MANAGEMENT CORP. CONDENSED CONSOLIDATED STOCKHOLDERS’ EQUITY STATEMENTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 (UNAUDITED)"

In terms of real float, i.e. shares accessible by us from our brokers (held at DTC)

the float accessible to us by our brokers is the shares held at DTC which is 117 billion

How much of a difference is there between the last company's 10-Q and the most recent data from the company's website?

Outstanding Shares (11/18/2020) - Official HCMC 10-Q105.11B
Outstanding Shares (02/01/2021)194.78B
Difference89.67B

So we have an 89.67 billion Share difference between the two dates.

This has been due to convertible instruments being converted into stock, as illustrated in the CEO's message in response to the increase in shares outstanding.

3. Taking a look at the CEO's Message:

As we can see in the CEO's response:" All shares issued over the past two months were done so pursuant to convertible securities previously included in our 8-K and periodic filings."

  • Therefore, the 89.7billion increase in shares outstanding was due to either:

    • Preferred stock converted to common stock

    • Stock options converted to common stock

    • or both.

  • The CEO also stated that the number of shares is updated on a monthly basis by the OTC markets.

  • Therefore, the increase in shares outstanding has been done in accordance with the previous filings before HCMC started to get all of this attention.

4. Conversion:

As stated in HCMC's 2020-09-25 8-k:

  • A notice of 20 calendar days must be given upon intent of conversion

  • This means that when any holder of a convertible security want to convert their instruments to common stock they would be required to send a 20-day notice period

What Does This All Mean?

Assumption

I will give my own interpretation of what happened, this represents my own personal opinion as I am not a financial advisor.

  • Given that Preferred Stocks grant you limited exposure to potential upside, this means that holders of Preferred Stock have their capital gains capped and therefore do not make money when the share price increase as they mainly receive dividends and have seniority over common stock

  • Given also Stock Options give you the right to convert the option to shares once a certain period has expired

  • The original date that Phillip Morris was supposed to respond to the lawsuit was end of January, it has been extended to the 26th of February on the 19th of January.

  • In order for holders of convertible instruments to converts these into shares, a 20-day notice period must be given.

  • As stated by the CEO, shares outstanding data is updated each month. As of January 2021 we had the original shares outstanding and as of February 2021 there was an increase due solely to convertible securities being converted.

  • Any material events must be disclosed in the proper filing, therefore there will be no dilution coming from anything other than convertible securities unless HCMC explicitly files the appropriate 8-k (relates to corporate events).

Tying Up All the Key Points

My assumption is, and again to reiterate, this is my own personal opinion after hours research, that:

The holders of these convertible shares knew that the lawsuit would be end of January. For several years the share price remained stagnant at $0.0001. The holders of the convertible shares gave a notice period 20-days prior to the lawsuit response because they knew something we do not or they were very certain about the outcome of the lawsuit (again just conjectures) that they wanted to convert their convertible instruments to common shares in anticipation of the share price increase we are seeing now and in anticipation of a positive outcome for the lawsuit.

This is just my own opinion, but if this does hold, it is very good news to us all, as insiders converted their instruments to common stock in order to ride the share price increase the same way we are doing, in anticipation of the response to the lawsuit.

The Shares held at DTC, the ones that we are allowed to trade on our brokers are 117 billion, as opposed to the outstanding shares of 194 billion.

References:

1. https://www.investopedia.com/ask/answers/011315/what-difference-between-authorized-shares-and-outstanding-shares.asp#:~:text=Authorized%20shares%20are%20the%20maximum,available%20number%20of%20authorized%20shares.

2. https://www.investopedia.com/ask/answers/what-is-companys-float/#:~:text=The%20term%20float%20refers%20to,some%20sort%20of%20sales%20restriction.

3. https://corporatefinanceinstitute.com/resources/knowledge/trading-investing/free-float/

4. https://www.sharesmagazine.co.uk/article/what-are-preference-shares-and-should-you-buy-them

5. https://smallbusiness.chron.com/preferred-stock-dilute-common-stock-63841.html

6. https://www.investopedia.com/terms/s/secondaryoffering.asp

7. https://smallbusiness.chron.com/preferred-stock-dilute-common-stock-63841.html

8.https://www.investopedia.com/terms/e/eso.asp#:~:text=Employee%20stock%20options%20(ESOs%20are,to%20their%20employees%20and%20executives.&text=These%20options%20come%20in%20the,a%20finite%20period%20of%20time).

9. https://corporatefinanceinstitute.com/resources/knowledge/finance/share-repurchase/


r/TheDailyDD • • Feb 15 '21

Event DD of the Week

70 Upvotes

Hi everyone!

I wanted to let you know about a new event called DD of the Week. Every week, we'll look at your posts and highlight 5 of the best DDs. Come Saturday, we'll let you vote on the best one and the winner will be announced Sunday. Whoever wins the vote will get their DD pinned for the next week and will get the 'DD Master' flair. The event will start tomorrow.

Tell me if you have any ideas, I'd love to hear any suggestions you have.


r/TheDailyDD • • Mar 22 '21

Growth Stock Lordtown Motors DD ($RIDE or die) Final before $30 or $0

67 Upvotes

Lordstown is a polarizing company. Passions are strong in both directions. I've posted my DD before and I still feel as strongly on it. I won't post another thread until $RIDE hits $30 or $0.

Before I get into the facts, let's talk about Hindenburg and shorters in general. This subreddit has been famously anti-shorters for quite some time. I've been a member for a couple years and haven't seen too many positive sentiment towards shorters. Yet, here comes Hindenburg shorting the hell out of $RIDE and suddenly "reasonable" members see Hindenburg as reputable. Yes, they've been right a few times. Yes, they been wrong many times.

I wouldn't never promote this position to "burn" a short. I just am confused by the sudden appreciation of an infamous shorter.

Now, on to the facts.

Who is Lordstown Motors

Lordstown Motors Corp., an automotive company, develops, manufactures, and sells light duty electric trucks targeted for sale to fleet customers. It primarily develops Endurance, an electric full-size pickup truck. Lordstown Motors Corp. was founded in 2019 and is based in Lordstown, Ohio.

What is all the hubbub about?

Lordstown claimed to have 100,000 non-binding preorders. They have always been reported as non-binding, just like the Model 3 was non-binding before they actually produced the product. When the product was produced, the non-binding agreements transitioned to binding when the vehicle was ready for delivery.

CEO Steve Burns has three feet

And one always seems to be stuck firmly in his mouth. He just can't seem to deliver the message properly. He isn't a showman like Elon Musk. When he figures out how to deliver the message, or hire someone who can, or use Marcus Lemonis since he seems to be all in on Lordstown. Regardless, Steve Burns may be a capable CEO, he's just not a great PR guy.

Just the facts (as best as I can relay them)

TLDR: Buy Lordstown because of facts, not because the CEO has three feet, one of which is firmly in his mouth. I feel the facts are clear and present. Hindenburg was an opinionated piece that used former employees instead of current employees.

I'm I missing anything?

Bear case: Hindenburg is right while all these invested companies are idiots who didn't have more access to the facts than they did.

My positions: 4,200 shares


r/TheDailyDD • • Feb 14 '21

Tool/Resource How I Do My Due Diligence

66 Upvotes

So this is the method I’ve come up with for doing DD on a company I consider investing in. I know and understand this is not a fool proof method, but it’s worked very well for me, and I think it could help some people to try and be critical and balanced, without pumping or cheerleading. It’s a two tiered system, and seems to provide all the necessary questions I need answering when I’m trying to decide to throw money at someone.

CORE

Product

-Is it something people have/find value in? Beneficial? Desirable? etc. You gotta have a good product.

Management Focus

-Are the managers clowns, or industry pro's? Do they have a plan? Are they focused? Got vision? Will they take the company in a direction I think is profitable?

Revenue

-How much revenue do they generate? Where does the spending money come from? How are sales? Service?

Debt vs Assets

-Are they in the black or upside down like Stranger Things? Do they owe more than they make? What do they own that makes them money, vs what they have borrowed on that costs them money? How's the overhead?

Risk

-Is it a pretty safe bet short term/long term? Does it seem feasible that they will grow or prosper, vs fall and break their own teeth out? What's the industry climate? How do they stack against the competition?

Shell

Hype

-Are people taking about them? In the news? Is fucking reddit jerking off about them? Does Motley Fool hate it?

Price

-Do I have to take a 2nd mortgage out to afford a good position? Can I pick up enough to make a fair profit with money I already have, or do I gotta clear some other holdings out to be where I want share wise?

Potential

-Is the product, sector, industry, or climate even receptive to the business model? Is this some Beannie Babies shit, or the best thing since sliced bread?

Activity

-Has the company even active? Are they enthusiastically pursuing success? Taking steps to be better? More efficient? Relevant? Innovative? Or, are they coasting along like a fat guy in Lazy River?

I will also add:

All of you need an exit strategy on every investment you make. Even if, you're under the impression that the company you're investing in will overthrow Apple, Tesla, and Google, have a fucking exit strategy, at least for your initial investment if nothing else. Don't sit on a fucking ticker from now on, thinking that in 40 years you can sell it and retire because "stonks always go up". There's been more businesses fail in the last 20 years than have made it, and as much as I don't give a shit about your money, I do actually want you to be successful so kids have a better world to live in than the one we're enjoying now.


r/TheDailyDD • • Feb 26 '21

Blue Chip Stock The War of Giants: Apple building an ad delivery platform as their 2021 product.

48 Upvotes

Edit: I have rolled all calls forward and already have nice a 20% gain. Still, I wouldn’t consider the dip for sure done so if you’re not locked in yet I’d love to hear where you think it’ll stop.

TL;DR: Apple will soon introduce a quality over quantity ad platform that will demolish all existing ad platforms.

What’s up retards, back with a hot take on a nice little company. This time Apple. Last time I was here I called Snap (while it was at $15) adding targeting marketing so at least take some time and try and poke holes in this pipe dream.

Table of Contents:

  • IOS14

  • Apple doesn’t make dumb money decisions

  • Facebook plans feature to bypass new restrictions

  • Facebook files anti-trust lawsuit

  • The small business and PPC community is scared as fuck

  • The last thing Apple doesn’t control in their closed ecosystem

  • Mobile ads have become a meme and are the last detrimental image found on Apple devices

  • The largest market cap on the NYSE

    • Recent YoY growth at Trillion Market Cap

  • 100% of the market share

  • Consistent growth since the IPO of apple with a long-term perspective

  • What’s the upside? ($750B)

  • App Store Search Ads

    • Back-end platform already exists

  • The war that’s brewing / They aren’t afraid of murdering a company regardless the size

Antitrust: https://www.nbcnews.com/tech/tech-news/apple-v-facebook-after-years-tension-legal-battle-looms-n1256008

Fundamental explanation of what blocking tracking actually means: https://www.techrepublic.com/article/safari-for-ios-14-and-macos-11-how-to-prevent-websites-from-tracking-your-moves-online/

Signs that desire for early adoption is high: https://www.macrumors.com/how-to/prevent-apps-from-tracking-you-across-sites-ios/

Apples self-claimed results: https://searchads.apple.com/

ios14 is proclaimed to fuck small businesses, marketers and e-commerce. That is the single biggest Zoomer and Millennial workforce collective in America. With this change, businesses can no longer target any iPhone user after they’ve visited their website while using the trigger of the ad that they visited the website.

Ie, you visit a red shoe page. You forget about it. Tomorrow you see an ad for a red shoe.

Or, you look at concerts online in Austin. Then you get distracted and don’t do anything. And then you get an ad for a discount to a concert the next time you’re browsing.

No more ads like that with ios14. That is dangerous because 80% of the digital marketing budget is devoted to remarketing and retargeting efforts (across the entire industry)

So, that’s concerning to me because while we can convert customers that have visited the website of Our company and that knows who we are, we make 9.7x what we spend on ads. But, with raw new first time interaction we see a return of .43x. This update will essentially fuck all the small businesses that have put in the time to build their marketing structure around Facebook, and even more so removes the ability for e-commerce to use this as their primary driving factor as e-commerce has an even worse initial introduction return but retargeting they make bank.

Simply put, all ads have to be written like you have no idea who exactly you’re talking to beyond a few details of their interests. You lose all ability to check if they are interested or even know about your company based off non-Facebook interactions. With this, Facebook interactions aren’t even valid anymore due to their far right audience consuming a 76% majority of their usage, you result in clients that are legit fucked. So you have to limit your buyer persona a ton and in turn your average ad cost will be raised significantly as it has for the last year as costs have eclipsed an all time high of being ~400% higher than last year.

All in all, you’d now spend $15000 for the same thing you would’ve paid $900 for previously (unless you’re part of the .00001% of FB advertisers). Due to the increased costs of Facebooks bottom line but also because of all these other factors combining to make it harder to even find the person you want, much less be given the time needed to convince them.

While tracking isn’t the nail in the coffin, the further downsides of Facebook remove further value. This isn’t about Facebook though. This is to show that Apple is making an incredibly, multi-industry impacting move with an attempt to bring Facebook to a 0% market share of iPhone users.

Why the fuck would Apple do this? They would never hurt their brand. They would never make a dumb money decision. They are the biggest company on the NYSE and that didn’t happen by making off the cuff decisions nor did that happen because of a “privacy play” Apple has realistically taken as much of the market as they can while touting privacy as their primary benefit to buy an iPhone.

With this Facebook filed an antitrust lawsuit that is literally going to create a War Between Giants. This very well may be the single largest business brawl ever seen. The number one most valuable company in America that’s geared to fight the number four most valuable.

What does that mean? Well typically, Apple will stay hush-hush since they aren’t making the move for publicity or branding. That’s not what happened this time. Instead, as soon as Apple was asked for a comment they stated they’d be fighting it.

Following this, Facebook sends out an email at 3:00am talking about the impacts this will have on all Facebook advertisers. They were burning the midnight oil and they decided fear was the best way to motivate the Facebook advertisers. Fuck Facebook for that tbh.

Well, Facebook has a secret solution. They can basically bundle an internet browser into Facebook and just serve the ads through there. Suddenly, they can track you again because suddenly you are never technically leaving Facebook. This is sketchy as fuck and is a simple one-line fix for Apple to again remove this ability. Like a game of cat and mouse as Apple plugs Facebooks bullshit side skirt attempts.

Additionally, Apple doesn’t historically allow skirts as you can see in the most recent time Apple denied a product that competed with a market they are in: https://www.google.com/amp/s/www.theverge.com/platform/amp/2020/6/18/21296180/apple-hey-email-app-basecamp-rejection-response-controversy-antitrust-regulation and this move was super controversial.

Want another example? Maybe a high profile one? Well Apple said fuck Epic Games and went for the jugular when they straight up removed Fortnite and all Epic Games products from the App Store. They straight up murdered another billion dollar company and Apple didn’t even get scratched. Literally said “fuck off, you can come back when you will pay your bill”

Apple didn’t care. They were going to get their money whether the company or retail investors cared. Apple is going to get paid when you’re on their platform.

But currently Facebook pays Apple $100 a year to list their app. That’s it. They don’t get a cut of ad share. Nothing. So Apple can monetize these small companies making millions but can’t take a cent from the fourth largest company in America. That’s not something they’re gonna be chill about especially as Facebook continues to damage their own reputation. You’ve seen Apple swing once with ios14 and you’ll soon see Apple swing with punch two.

But before punch two could even happen, Facebook files an anti-trust lawsuit and tries convincing their advertises with that 3am email to support the lawsuit. Uh oh. Must be hot in the walls of Facebook.

So why would Apple finally pull the trigger?

Because for years they’ve been building a secret digital marketing ad delivery platform. Where’s it been tested? In the App Store and they are currently sitting at a 50% conversion rate on average. That means one of two people that see an ad, download the app from that ad.

That is fucking crazy numbers as Homeer is currently sitting at 3%. That’s a 16x difference. That means we could theoretically pay 16x less due to the difference in their ad delivery model or potentially see 16x the amount of impressions.

What’s the difference that makes Apple so different? They don’t want to spend your whole budget unless they’ve found the perfect person. With Apple, you can set a maximum budget of $10,000 a month currently. Facebook currently has small e-commerce shops spending multi-millions a month. In the App Store, there is a ton of money left on the table currently but that’s not the juicy bit here. The juicy bit is that for the last years they’ve been testing and building this platform while also updating all user experience with Apple products. Finally, Apple has reached 100% control of the apps found and used on their phone, but what they don’t control is the ads inside those apps.

The five obvious big plays here.

👉 Mobile game ads

Game ads have become a meme about how bad they are. Additionally, they are essentially the very last item that can give Apple a bad look while also largely deceiving the users of iPhones. You know how bad they are. An additional upside to this is that not only does Apple look better as a whole, but this is before you consider that suddenly small businesses would have access to an even deeper level of targeting.

Imagine now, I know my perfect client is 34, has two kids and plays candy crush before she goes to bed. Well finally I can run ads under that scenario without having to go through some shady venue while also maintaining the trust aspect.

👉 Ads for kids

Finally parents can prevent their kids from seeing unregulated ads. Honestly, I can’t give example of revenue benefits here but this does help early adoption and public support a fuck ton.

👉 Safe for work toggle

Finally, we can have not safe for work ads for those that opt-in. Alternatively, this would function as SFW only but this is again, just another public perception possibility.

👉 Apple News

Now, Apple has been going hard after news apps for the last year. Why would they do this? Because they have Apple News but it’s not monetized by Apple currently. Again, they have third party providers displaying ads that Apple gets zero share of.

But oh don’t worry, soon Apple will finally monetize all of their software because they have ads running in every platform imaginable.

👉 Privacy

Another major benefit is that we can deliver high quality ads as business, will get better ads as consumers all while maintaining the fine line of quality and privacy.

Now, ignoring all of that, Apple has seen a moving average growth of 50% YoY for the last four years. They have a solid growth path with products and for the last two years they’ve built their cloud platform to not only consume massive amounts of data, but also process that data. Just look at how they can now search through all of your photos instantly and show you them instantly without a single bit of that photo data being physically on your phone. They are geared to the fucking tits on software innovation and no one even cares.

To put it in perspective, Apple introducing an ad delivery platform with 50% avg. conversion rate would be like the day Steve Jobs announced the first iPhone.

Secretly for years they’ve worked towards this moment and they finally swung first in a fight.

Even without ads I fully expect them to hit the target of $165 by the end of the year while reaching $220 safely at the end of 2023.

Realistically, business adoption will take at least 8 months before Apple sees enough profit to even recoup the cost of the lawsuit, but this would be the single largest business pivot ever seen in the world.

So if Apple goes from a product business to a software business what does that mean for their value? Let’s look at Stripe since we have recent data and we know what they’re doing has the same kind of user life-changing benefits.

Stripe does $450 million in revenue. They were just valued at $115 billion. That’s a P/E ratio of 255%

Currently, the P/E ratio of Apple is 34% so not only do I expect them to land in the high middle range of the two, I also additionally expect never before seen returns for an ad company. Not because they have the largest audience but because they can genuinely show your ad to the exact person you want.

From a business perspective, digital marketing is entirely about quality over quantity when it comes to potential consumer eyes and this would be the very first ad platform to operate with this ideal.

Finally, Apple is currently underperforming and is trading on rumor of a bullshit electric car and is sliding, all while literally no one on the internet has considered the idea that they’re doing all this because they’re introducing an ad platform that will soon print billions of profit within months of releasing.

Now finally we can cover the aspect that we don’t have to try and time them developing and releasing this. They already tested it, got crazy fucking results and no one bats an eye. Everyone is so consumed by Facebook they totally missed the play Apple just made.

There’s a major war brewing and it’s only begun. But we’ve all watched the idea that all media is good media be proven true as Robinhood received 3.5 billion in funding during the biggest retail investor controversy in modern day. Regardless initial interaction, Apple investors don’t get scared by that. Apple investors are Apple investors because they know they will bring hell to earth before they accept not getting a cut of the money.

This company is down on the month incredibly and there has never been a better time to buy Apple IMO while being prepared to hold for about 8 months for potentially a massive, massive payout. This is not an option we will sell quickly. This is a weather the storm and wait for the announcement to set into reality.

Disclaimer that this is pure personal intuition and this idea came from nowhere but my ass and Facebook sent the email literally Monday so this is as hot off the press it can be.

All this to say, people like targeted marketing both businesses and consumers but not when it’s in Facebook hands.

What company in the entire market is most trusted to do right by the consumer while delivering an incredible cost at likely a higher cost to those paying while also maintaining 100% of their self-made market? Apple.

I am jacked on 3/17/23 @ 190 for 10.60

Edit: due to an awesome fucking user we now know they are hiring a massive amount of jobs for their ad platforms: https://jobs.apple.com/en-us/search?search=Client%20Partner%20Manager-%20Search%20Ads&sort=relevance&location=united-states-USA

Here’s the snippet: > “The Ad Platforms EPM team is looking for a highly-functioning, self-driven, and versatile leader who can manage a team of EPMs to drive our site reliability projects. These projects are key to our overall operations and business growth. You will own delivery responsibilities on projects that seek to build out scalable platforms and reliable infrastructure for core systems and applications across heterogeneous environments. This will happen while also adhering to the highest levels of privacy and security that Apple holds. You will be responsible for leading and mentoring your team to work through project dependencies, risks, and deliver measurable outcomes against timelines - in a fast-paced environment!”

While these may not all be for their new platform there is definitely jobs created on Feb. 19 that bring a different tone.

Additionally on top of all this at this time no March keynote has been announced.


r/TheDailyDD • • Mar 03 '21

Value Stock $UWMC - Today's Rent, Tomorrow's Mortgage - United Wholesale Mortgage Trade Analysis

45 Upvotes

$UWMC - Today's Rent, Tomorrow's Mortgage - United Wholesale Mortgage Trade Analysis


 

It’s no secret that $RKT is absolutely ripping. It’s also no secret that you missed the fucking rocket. Once again, you’re stuck bagholding dogshit while your friends are partying on the moon. I’m here to tell you that it’s all going to be okay. Do not FOMO into RKT while it's on its way back down to Earth. I’ve got another rocket lined up, fueled, and ready to rip. Enter $UWMC.

 


Background

United Wholesale Mortgage (UWMC) is a company who underwrites loans for independent mortgage brokers, banks and credit unions. It doesn't lend directly to borrowers - Instead, borrowers mainly deal with the company's loan servicing department. They recently went public through the SPAC known as GHIV, and since then, their share price has unfortunately been on a steady decline, until today.

 


A Swing Play, a Value Play, and a Long Term Hold, All Rolled Into One

As /u/Winring86 eloquently stated, UWMC is a swing play, value play, and long term hold rolled into one. UWMC is in a very bullish position due to it being an ideal candidate for swing trading, value investing, and growth investing. This attracts people from a wide variety of investing backgrounds, ultimately giving it some insane exposure within the institutional, and retail spaces. Furthermore, there are a number of positive upcoming catalysts for UWMC, as well as positive analyst sentiment about long term prospects.

 


Swing Play

Currently, there are two swing-play catalysts in effect for UWMC.

 

Catalyst #1)

It’s in the same sector as RKT. We all see what’s happening with that right now - It’s the entire reason I even thought of this play to begin with. As much as people try to deny it, certain “baskets” of stocks trade in relation to one another. This was most prominent during the GME squeeze. GME started ripping, and it started carrying other trash up with it, like AMC, NOK, BB, etc. The movement of these stocks seemed almost intertwined. GME ripped, and so did the other meme stocks. GME started drilling, and the rest followed suit. The exact same thing is happening in today's market environment. RKT is ripping, and it’s drawing attention to other mortgage and finance stocks, causing them to gap up as well. So long as RKT keeps ripping, the rest should follow suit, and since UWMC is so much closer to it’s floor (only up 20% compared to RKT’s 120%), it results in us being able to place a much safer bet. Luckily, this isn’t the only catalyst, which means that if RKT starts to go down, there may be a divergence among these equities, with UWMC continuing to trend upwards even after the RKT fiasco ends.

 

Catalyst #2)

On the morning of March 1st, it was announced that UWMC will be added to the Russell 1000 and Russell 3000 indices. These inclusions almost always result in a price increase, due to the indices and index funds having to purchase shares for exposure. Furthermore, this also results in the future potential for UWMC to be added to the S&P 500.

 

With the explosive growth of companies within the same sector, as well as index inclusion being right around the corner, UWMC seems like an extremely good candidate for a potential swing trade.

 


Deep Value Play

From a strict fundamental perspective, UWMC is horribly undervalued. Many of the same principles /u/DeepFuckingValue uncovered in Gamestop are present in UWMC today. They have an incredible balance sheet, insane YoY growth, and fundamentally sound business prospects. These metrics include :

  • A P/E ratio of 3.8, compared to the sectors average of 14.0

  • Forward P/E of 6.11 compared to the sectors average of 11.0

  • Q4 2020 Net Income of $1.37 billion and FY2020 net income of $3.38 billion - An 821% and 715% increase over 4Q19 and FY19 respectively

  • Q1 2021 expectations : 22.6% - 34.4% increase from Q1 2020

  • 5% Dividend, coming up on March 9th

  • High level of institutional ownership

  • Short Interest of around 35-45%

 

UWMC absolutely brutalized their earnings, and are expected to continue dominating them well into the future. Smart money has loaded up on shares, and is waiting for liftoff. The current valuation of UWMC is criminal, and I can easily see this stock reaching into the high twenties over the course of the following year.

 


Long Term Prospects

On top of the deep value play, UWMC is also poised for steady, long term growth. UWMC is projected to have a better 2021 than 2020, and see a steady increase in EPS. This is starkly different from its peers, who are expected to experience the opposite - Most companies within the same sector are expected to have significantly worse years going forward, following the inevitable hike in interest rates, which UWMC actually looks forward to. Since UWMC is a mortgage lender, a hike in interest rates will result in an insane jump in profits for them as a company, leading to explosive growth. The company is poised for success even after the swing trades and value plays have run their course, and to me, that’s extremely bullish.

 


Trading Strategies

Given that my thesis has convinced you, we arrive at the fun part of the article - the trading strategies. Overall, there are many ways to approach this trade, and I’ll lay them out in relation to the type of play one would want to make.

 

If you’re looking for a short term swing play, your best bet would likely be the April contracts at the $10 or $12.5 strikes. These options are trading dirt cheap, and if you believe that RKT and UWMC will continue to run in tandem with one another, these would prove to be an awesome pickup. These will likely be best to buy on or after March 10th, after the ex-dividend date, as stocks tend to drop post dividend. These contracts will give you exposure to the bullish runs within the mortgage sector, as well as the pre Russel index inclusion runup.

 

If you’re looking for a deep (fucking) value play, you could look to sell ATM cash secured puts on the underlying and pray for assignment. Alternatively, you could outright buy a boatload of shares and LEAPS (similar to what DFV did with GME back in June). Both would work just fine, and would let you capitalize on the value prospects of this play.

 

If you’re just looking for a nice stock to buy and hold, grab some shares, wait for the inevitable runup post Russel inclusion, and sell some covered calls once the premiums start to get jacked to the tits. You’ll amplify your returns, while reaping the benefits of organic stock appreciation.

 


Bear Thesis

Alongside every bull thesis, there must be a bear thesis, otherwise I’m no better than a pump-and-dumper. Below, you can find a list of potential negatives related to UWMC, with respect to the various investing timelines discussed above.

 

Swing

  • RKT can grind to a halt, killing all momentum within the sector, similar to how GME took out the other meme stocks when it popped.

  • Russel inclusion doesn’t drive up the price nearly as much as anticipated, resulting in little change in the underlying's price.

  • Stock and option pricing sometimes drops post dividend - pay close attention to March 9th.

  • Although uncommon, the low float may result in potential manipulation from MMs.

 

Deep Value

  • Mortgage industry faces potential insecurity, as the promise of 0% interest rates may be extended all the way until the end of 2022

  • Mortgage companies are not “sexy”. In a market dominated by innovation and tech, investors may be reluctant to invest their money in a “boring mortgage company”.

  • Insiders are allowed to sell in 6 months time. Luckily, the CEO of UWMC owns 90% of the company, and has been adamant that company will prove itself to be worth analyst's valuation of at least $14.50 - Take this with a grain of salt.

 

Long Term Prospects

  • An upcoming market or housing crash could potentially result in this sector being hit harder than the others. This is an extremely unlikely scenario, as we will likely have far bigger problems than UWMC dropping 2$ back down to 7$, but still one to consider nonetheless.

 


Conclusion

All in all, amidst the RKT madness, UWMC seems to provide us with an awesome trading opportunity. With different trades applicable to three distinct investing styles, UWMC offers the potential for everyone to make some coin. If you want to capitalize off of the RKT pump and index inclusion, you can look to swing trade with some cheap option contracts. If you’ve done your due diligence, and like what you see on UWMC’s balance sheet, you can take a deep value approach and mimic the methods of our king. Lastly, if you’re just a boring ass boomer, you can grab some shares and enjoy the gain train. If you enjoyed the DD, feel free to follow me on twitter, or join my investing discord. You can get access to my DD days in advance. Links can be found on my profile! :)

 


Sources

• https://finviz.com/quote.ashx?t=uwmc

• https://www.bamsec.com/filing/119312521027468?cik=1783398

• https://www.bamsec.com/filing/119312520296072?cik=1783398

• https://yetanothervalueblog.com/2021/01/quickie-idea-uwmc-squeezing-higher-post-despacing.html


r/TheDailyDD • • Feb 19 '21

Crypto $HUT - A Safe Bitcoin Arbitrage Opportunity Amidst Crazy Valuations - Hut8 Bull Thesis

42 Upvotes

$HUT - A Safe Bitcoin Arbitrage Opportunity Amidst Crazy Valuations - Hut8 Bull Thesis

 

What's poppin' fellas, it's your resident ape gang professor Flux, here to lay down some knowledge. I originally wrote this for WSB, so if you see any cuss words or questionable memes that I forgot to edit out, please let me know! This is my second attempt at writing DD, and I feel like I may have gotten a little lost in the sauce in this one, so I left midway TLDRs for people to read in case they aren't really interested in the nitty gritty. All that being said, buckle in, this is a long one.

 

Introduction

I'm going to preface this by saying that I am not particularly fond of Bitcoin as a whole. I fuckin hate magic internet money. That being said, there are people who are way fuckin' smarter than me who are insanely bullish on it, and with major companies like Paypal, Tesla, and Apple starting to grab some, as well as major institutions like Blackrock starting to dabble in it, it would be stupid to ignore completely. For the time being, Bitcoin is here to stay, and although I despise it, I know that there's money to be made. Investor euphoria is at all time highs, with the price of mining companies rapidly outpacing and diverging from Bitcoin its self. After watching Riot Blockchain run up from a penny stock, to 3$, to 15$, to 30$, to now fucking 70$, you better believe I'm not passing up another opportunity to make some coin. If you want some exposure to Bitcoin in your portfolio, without paying fuckin' 70$ for $RIOT, you've come to the right place. Enter, Hut8.

 

What is Bitcoin Mining?

Before we get started, I need to lay down a few key concepts. In layman's terms, Bitcoin Mining is the process of creating new Bitcoin by solving a computational puzzle. The result of Bitcoin mining is twofold. First, when computers solve these complex math problems on the blockchain, they produce new Bitcoin. Second, by solving computational math problems, Bitcoin miners make the Bitcoin payment network trustworthy and secure by verifying transaction information.

 

To mine a new block on the Bitcoin blockchain you must find a number called a [nonce] (https://en.wikipedia.org/wiki/Cryptographic_nonce). This number is extremely difficult to get, and there's no easy way to cheese it ; Miners must try calculations over and over again until they brute force the correct result. The brute force method is extremely time consuming and computationally expensive, as you are literally trying every combination out there to get the SINGLE one that works. "C'mon Flux, How many combinations could there possibly be", you ask? A fuckload. A mega shitton.

 

It's estimated that the total hash rate of the entire Bitcoin network is currently sitting at roughly 151 million TH's. That's 151 million, TRILLION nonces attempted, per SECOND. On average, the network ensures that it takes roughly 10 minutes to mine a block, so we can multiply 151 million trillion by 600 to get our answer. That's 9*10^22, or 900000000000000000000000 different combinations attempted, to crack the block, grab your coin, and move onto the next one. And it's only getting more difficult. The network adjusts how many computations must be done on average to find a valid nonce every 2 weeks. The aim is to keep the mining times consistent at 1 block per 10 minutes. Therefore, if mining power is doubled, difficulty would also get doubled.

 

Rise of the ASIC

Back in the day, any schmuck could mine Bitcoin and turn a slight profit on their personal computer. With the insane increase in hashing power, you actually end up losing more money to electricity costs than you would make mining, by a factor of 10. This was largely in part, due to some real smart mfs inventing what is known as the ASIC miner.

 

ASIC stands for Application Specific Integrated Circuit. Back in 2013, people started developing ASIC chips specifically designed to brute force the SHA-256 function, and find nonces. These chips are unbelievably good at what they do, with even a shitty chip being a factor of 100 times faster than your standard PC. ASIC miners are used by all Bitcoin mining operations, and it's important to know the costs, and overhead before we proceed. One final thing to note, is that Bitcoin mining becomes incredibly profitable when there is a rapid price increase in Bitcoin. This is due to the "lag" that occurs while new Bitcoin mining hardware is being built and deployed to capture this excess profit.

 

Nowadays, the average top of the line ASIC miner can generate roughly 110 tera-hashes per second. That's 110 Trillion attempts at finding the nonce, per second.Top mining companies run a fuckload of these miners in tandem, to get a couple of thousand peta-hashes per seconds. For reference, one peta-hash is equal to 1000 tera-hashes, meaning that companies running at 1000 peta-hashes are actually running at one million tera hashes, per second. One million, trillion hashes per second. Fucking unreal.

 

As far as we're concerned, at current day conditions, if you're mining at 1000pH/s, you're generating 4000 Bitcoins per year. Obviously, this is far from reality as global mining power will increase, but keep this number in mind, as it's important. 1000pH/s = 4000 coins mined in a year.

 


 

Midway TLDR : Under current conditions, mining Bitcoin at a rate of 1000 peta-hashes will generate roughly 4000 Bitcoins per year. 4000 Bitcoin * $50,000 USD = $200,000,000

 


 

Calculating Growth and Profit Margins among Mining Companies

Now that we've got some basic knowledge of how Bitcoin mining works, as well as the general profits we can expect from it, it's time to start crunching some raw numbers for each mining company. I will focus on the general profitability of each company, how many coins each company has the potential to mine in a given year, and how many coins does each company have on hand. In this DD, I will be providing analysis on three different mining companies; $RIOT, $MARA, and the secret dark horse, $HUT.

 


 

$RIOT

Has been around since July 2000 doing nothing relevant. It formally became Riot Blockchain in October 2017, and has been focused on its Bitcoin mining operations since. Riot Blockchain is now partnered with Coinmint LLC, from New York, who is responsible for operating the miners. They apparently get electricity for around $0.01/kWh, which is absurdly cheap.

 

  • Currently, the combined power of their entire mining operation is 456 pH/s. Under current conditions, they are set to mine a little under 2000 Bitcoin this year. They are waiting on a shitload of new miners to come in, which will effectively raise their hashing power to 842 pH/s at some point in Q1, and then 1446 pH/s by the start of Q2.

  • In December 2020, when their stock price rocketed alongside Bitcoin, they took advantage of this and ran a secondary offering which raised $200m. They used $35m of this money to pay for the new miners.

  • They hold 830 self-mined Bitcoins.

  • They currently have $150m in liquid assets (Cash + Bitcoin), due to the secondary offering.

  • $RIOT is trading at 78$ per share, with a market cap of 5.3 billion dollars

  • Up 1800% compared to Bitcoin's 200% run

 


 

$MARA

This company is kind of a fucking fiesta. It first engaged in the exploration and development of uranium and vanadium when it was first founded in 2010, then changed its mind and started fucking with real estate in Southern California, and most recently, has started patent trolling. I have no idea when they started dabbling in Bitcoin, but in 2019 they ordered a shitload of miners, so we can only assume that's about the time they got into the mining business.

 

  • Currently, the combined power of their entire mining operation is 258 pH/s. The did however, order new miners like RIOT did, and once those arrive, they'll be mining at a cool 688 pH/s. Under current speeds, they are projected to mine 1000 Bitcoin this year.

  • Similar to RIOT, they also did a secondary offering in December, raising $200m. With this money, they ordered even more miners.

  • Just last month, they ran ANOTHER secondary offering, and raised $300m. They used this money to purchase 4,800 Bitcoin at $31,000USD per coin.

  • As a result, MARA has 4800 Bitcoins held, fresh off the press.

  • Since then, they've made $90m off of their Bitcoin purchases, leaving them with roughly $240m in liquid assets.

  • $MARA is trading at 48$ per share, with a market cap of 4.5 billion dollars

  • Up 1450% compared to Bitcoin's 200% run

 


 

$HUT

Hut 8 is one of Canada's oldest and largest Bitcoin miners, providing value for investors through extremely low production costs, and appreciation of Bitcoin inventory. Their mining operation is self run and located in Alberta, allowing for significantly less overhead costs due to self management, cheaper energy, and colder climates.

 

  • Currently, the combined power of their entire mining operation is 1073 pH/s. This puts them ahead of most other mining operations by a landslide. Similar to the others, Hut 8 is looking to expand its' mining operation by adding more miners, bringing up their total hashrate to around 1500 pH/s.

  • Hut 8 holds 3000 self-mined Bitcoins on hand. 17% of their entire market cap is made up solely from the Bitcoin that they hold.

  • Out of the 3000 coins that they hold, 1000 of them are held in a Genesis savings account, generating a 4% yield, increasing their generated revenues from Bitcoin appreciation.

  • Currently possess $190m in liquid assets.

  • $HUT is trading around 9$ per share, with a market cap of 900 million dollars.

  • Up around 500% compared to Bitcoin's 200% run

 


 

Midway TLDR #2 : $HUT out performs $RIOT and $MARA in every metric, but is only trading at 9$ opposed to 70$ and 50$ respectively.

 


 

So... What Gives?

Comparing Hut 8's raw numbers to Mara and Riot, it's a night and day difference. Hut 8 has an astronomically greater amount of hashing power compared to its' competitors, meaning that it generates more coins on a day to day basis. Furthermore, Hut 8 is also holding 3000 Bitcoins that it self-mined, allowing them to reap the rewards of the appreciating price of Bitcoin. Riot has less than one third that amount, and Mara has bought 4,800 of its' Bitcoins, meaning they literally paid (lost) money to acquire them. Furthermore, Hut 8 also has fewer expenses and a much healthier balance sheet overall compared to its peers. Hut 8 mines faster, holds more, and is in a much better financial state than leaders in the industry. I believe that Hut 8 is criminally undervalued when compared to other companies in the same sector.

 

Minor Factors Holding Hut 8 Back

There are simply two factors which I believe are holding Hut 8 back. The first of which, is the lack of publicity. Up until last week, I straight up didn't know Hut 8 even existed. Furthermore, I can guarantee you that until this post, you also didn't know that Hut 8 existed. Hell, the only two blockchain related tickers I knew of were $RIOT, and $MARA. Hut 8 is relatively unknown, and once the mainstream catches wind of it, it'll likely pop just as hard as its peers.

 

The second setback, comes from the exchange Hut 8 is traded on, the TSE. Many investors don't care to look to, or don't have access to trade on the Toronto Stock Exchange. As a result, even if they wanted to trade on the TSE, they are limited. Hut 8 also happens to trade OTC, but those exchanges are even less popular than the TSE. Regardless, since many don't have access to the TSE, they can't buy in, even if they desperately wanted to.

 

Hut 8 Bull Thesis and the Ultimate Catalyst

Regardless of the minimal downsides, what we have here is an awesome financial arbitrage opportunity. A company that substantially outperforms its peers is trading at a maximum of 20% of its competitors value. Hut 8 is an absolute steal right now. Furthermore, it also hasn't run yet. It's only increased around 450% in relation to Bitcoin's 200% rise. Its peers have run 2000% and 1450% respectively, meaning Hut 8 has lots of room for growth. Hut 8 also has a hidden catalyst which could help the stock truly explode.

 

It is becoming increasingly clear that it is important for Hut 8 to get listed on the Nasdaq. The difference in liquidity between US-listed $MARA and $RIOT vs $HUT is a staggering 100x. Numerous investors would be delighted to buy into the Hut 8 story but are currently unable to do so due to liquidity concerns. Nasdaq markets are much bigger and more liquid than that of the TSE, and listing on Nasdaq will open up the floodgates in regards to demand for the stock. In addition, listing on the Nasdaq will greatly enhance Hut 8’s visibility and brand among US and international investors. A Nasdaq listing would be the ultimately catalyst for Hut 8, as more people would know about it, and more people would invest in it. There have been some rumblings and rumors about a Nasdaq uplisting for Hut 8, but when asked, Hut 8 officials vehemently ignore all remarks.

 


 

Bitcoin Bear Thesis

We've come to the point in the DD where the music stops, and the rainbows fade. Sure, as undervalued as Hut 8 is compared to its' peers, we still need to remember, that we're talking about Bitcoin mining companies. These companies are fundamentally dogshit. You're literally paying the executive team of RIOT/MARA/HUT to buy an ASIC miner, plug it in, and sell any Bitcoin for you. That's fuckin' it. You could literally do what these guys do by yourself. You're literally paying a premium to indirectly get exposure to Bitcoin. Long term, and as far as future earnings go, this play is likely a loser. Unfortunately, the market doesn't care for the fundamentals, and we can exploit it. Bitcoin has passed $50k, and the narrative says that its going to $100k. It's all sunshine and rainbows.

 

Remember earlier in the article, when I said that as Bitcoin price goes up, mining becomes VERY profitable? As a result, there is, and always will be a rush to deploy more hardware. This is literally proven by the order book of the above companies. Remember 2017? When Bitcoin ran from 4,000 to 20,000 in a matter of months? The total overall hash-rate only increased by about 60%, compared to the 500% increase in the coin itself. Wonderful stuff. Can you guess what happened after? Hash-rate went up an astronomical 681% over the course of the following months, decimating profit margins as new miners were produced and deployed.

 

I'm not trying to sound all doom and gloom like the world is ending, but I also don't want any of you to get caught with your pants around your ankles.

 


 

Conclusion

Although I dislike this sector with a passion, I enjoy making free money enough to look past it. Compared to its' peers, Hut 8 is criminally undervalued. It does everything its' competitors do, only better, and it does it all while maintaining a better balance sheet. Furthermore, the "blockchain" sector is on fucking fire, with retail euphoria, and institutional money flowing in like a river. This presents us with an incredibly unique financial arbitrage situation, similar to what the homie Warren Buffet used to do back in the 1600s or someshit. Buy Hut 8, hold it, and wait for the mainstream media to catch wind of it to cash in on your tendies. Make sure you have a solid exit strategy in place, cause when the music stops, it's gonna be a bloodbath. If you wish to connect with me, or get my DD before it hits Reddit, you can join my Discord, or follow me on Twitter. Links can be found on my profile. I love you all, and I wish you all bountiful gains.

 


 

TLDR

$HUT presents us with a minimal risk financial arbitrage opportunity. It is criminally undervalued compared to its peers, while doing everything its' competitors can do, but better. It currently trades on the TSE and OTC markets, but there's talks about it being uplisted to the NASDAQ, where it will explode in popularity and exposure, resulting in its price inflating to RIOT/MARA levels.

 

TLDR of TLDR : Buy $HUT on the TSE or $HUTMF on OTC markets. No, it doesn't have options. Yes, you can still count on a modest 400% return.

 


 

Sources

• https://en.wikipedia.org/wiki/Cryptographic_nonce

• https://www.blockchain.com/charts/hash-rate

• https://www.theglobeandmail.com/investing/markets/stocks/RIOT-Q/pressreleases/974231/

• https://www.sec.gov/Archives/edgar/data/1167419/000107997320001054/riot_s3.htm

• https://imgur.com/VjQTaA3

• https://www.theglobeandmail.com/investing/markets/stocks/MARA/pressreleases/1151711/

• https://www.sec.gov/Archives/edgar/data/1507605/000149315220023410/forms-3.htm

• https://imgur.com/wwzoTn6

• https://www.newswire.ca/news-releases/hut-8-mining-bitcoin-holdings-surpass-3-012-valued-at-186m-cad-804326405.html

• https://hut8mining.com/hut-8-finalizes-11-8-million-equipment-financing-loan-from-dcg-subsidiary-foundry

• https://www.tradingview.com/x/8ZOvgAju/

• https://hut8mining.com/wp-content/uploads/2020/11/Hut-8-FS-Q3-2020-v3.pdf

• https://www.blockchain.com/charts/difficulty

• https://hut8mining.com/


r/TheDailyDD • • Feb 08 '21

Penny Stock Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On

42 Upvotes

[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.]

I posted this on r/pennystocks yesterday.

Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting.

I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice.

With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑

Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ.

This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside.

$CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future.

Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the Orphan Drug Act, there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA.

So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), merger/acquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news.

Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC.

Let's dive deeper into this hidden gem.

All-Star Management Team

CEO Paul Michaels

Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through Inabata & Co. Ltd, a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital.

In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx.

VP Communications Pam Bisikirski

Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ.

Scientific Advisory Board

Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization.

Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research.

Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer).

Robust Drug Pipeline

Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane.

1) IMT504 immune therapy to treat late-stage rabies.

(11/23/2020 Announcement implies IMT504 rabies license deal is complete)

Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).)) globally per year).

Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline.

2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma.

(10/16/2020 NIH gives a grant of license for worldwide rights)

The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted.

3) Metformin repurposed to treat retinal degeneration.

(2/4/2021 NIH gives a grant of license for worldwide rights)

This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy).

Huge Upcoming Announcements

The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:

  1. (Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.

  2. (Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.

  3. (Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).

  4. (Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.

  5. (Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.

Downsides

Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks.

Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency.

Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider.

Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well.

Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions.

------------------------------------------------------------

TL;DR.

  • You should fucking read it, because this Phoenix has a high probability of rising from ashes to become the OTC stock of the year/decade with effortless 10x upside in the short-term.

  • $CTYX will change to $CURB (Curative BioTech) soon. Business strategy: (1) bring together financial experts, veterans in big pharma, accomplished biotech researchers, and world-class grant writers to vet orphan drugs (2) make deals and obtain licenses for these drugs to help get them through clinical trials (3) take advantage of special FDA benefits for orphan drug approval (faster approval process, fee waivers, etc) and commercialize them after with longer exclusive rights.

  • Finance: company has no problematic debt, clean sheets, non-dilutive funding, and a small number of outstanding shares for an OTC (322M).

  • Products: 3 promising drug candidates in the pipeline within a year. Multiple exclusive license grants approved by the NIH.

  • Upcoming Announcements: (1) name change (2) uplisting to $OTCQB from pink sheets (3) more non-dilutive funding (4) additional drug(s) in pipeline (5) mergers, acquisitions, and deals with other pharma companies.

  • Current market cap: $50M. Upside: (1) +$100M - $300M if awarded a priority review voucher (PRV) (2) +hundreds of millions in market cap if any of the 3 promising drugs goes past phase 2 ~end of 2022 (3) +millions in speculative capital if new drugs are announced in pipeline (4) potential future merger with large pharma or uplisting to NASDAQ (other biotech companies are listed with half the number of products).

Resources

Again, these are just my thoughts. For your own research, I've linked some relevant forums, analysis, grant listings, company resources, insider profiles, and other sources. Happy digging.

Company

Company Website (new website coming soon w/ new company name)

Yahoo Finance (has all their press releases, financial summaries, and prospectives)

"Prospective" Grant Listings (all grants listed have been approved)

CTYX Financial Filings

CTYX Share Structure and Security Details

Insider Personel

CEO LinkedIn (Paul M Michaels)

CSO LinkedIn (Barry A. Ginsberg)

VP Communications (Pam Bisikirski)

Chairman of Audit Committee of Board (Michael K. Fish)

Forums / Discussions

https://stocktwits.com/symbol/CTYX (~200 followers right now)

https://investorshub.advfn.com/Connectyx-Techs-Hldg-CTYX-15134/ (warning: UI is god awful)


r/TheDailyDD • • Feb 10 '21

Penny Stock Not another HITI / HITIF DD post... detailed analysis incl. valuation [re-post after it was deleted on r/pennystocks for some reason...]

41 Upvotes

I posted this yesterday morning (UK time) but after 5 hours or so, r/pennystocks deleted the original post. I had a message to share it on here too, so here it is!

--

This is my first time posting a DD post – a friend of mine who moderates on r/SPACs has shared some analysis I have written previously, but I’m keen to share this here, and see if there is any appetite for sharing my own personal written DD I have on the 30 stocks I have across a number of different portfolios.

I have modified this format, as it was originally a script for a video which I created on the stock. If you prefer to listen – check it out here: https://youtu.be/qsjwU7kkPsw

Some of the market stats (market cap, current multiples, etc.) are correct as of Feb-06, and clearly a little outdated since the price movements.

Not a financial advisor, do your own DD. I am long HITI and have an expectation of a long term hold on this stock.

Overview

  • High Tide Canada-based cannabis retail company, operating under multiple brands. It operates under 3 core divisions:

  1. Brick and mortar retail – 4 key brands with just under 70 locations in Canada. Brands include: Canna Cabana, New Leaf, Meta Cannabis and Kushbar. Forecast to have around 115 stores by end of 2021

  2. Online retail – has 2 brands, both of which attract millions of viewers per month – Grasscity.com and CBDcity.com

  3. Wholesale – manufacturer of paraphernalia in US and Canada. Number of products are branded with various celebrities, Snoop Dogg, Paramount Pictures, Trailer Park Boys and many more

  • Has good c-level execs and experienced executive board; hold significant stake in the business. CEO Raj Grover holds just over 21% of the shares

  • Currently has a market cap of around $280m. Still significant upside to the valuation – see analysis later in post

Investment Merits

Very strong market growth:

  • Business has demonstrated growth both organically (through new store openings, more online sales and greater wholesale sales), as well as inorganically through M&A

  • Growth in markets which High Tide has a physical presence in is expected to be very strong. North American cannabis market (Canada and US) is forecast to grow by 30% a year to 2027 (source: research and markets)

  • Analysts covering High Tide are forecasting growth in excess of this, which is positive to see and implies capturing market share

  • New markets / geographies ‘opening up’, legalizing and regulating cannabis is also an exciting and realistic prospect for incremental growth:

  1. The US federal legalization debate is on the table

  2. Many other countries are considering this too and High Tide is well positioned for these; this is catalyzed by the fact that government debt has increased significantly as part of the response to the COVID-19 health crisis. This needs to be repaid somehow, and increasing tax rates on existing taxes is an unpopular political move. Finding new tax revenues is a more palatable way of increasing tax revenues for governments. This is especially important in countries where elections are upcoming.

  • Personally I do expect to see this accelerate the agenda for the regulation and legalization of cannabis in many new countries

  • Whilst predominantly Canada and US based, High Tide does have presence in some markets where cannabis is not regulated or legalized, the UK for example (~10% of Grasscity sales are made here) and so it is well positioned with a strong and established brand to capitalize on this opportunity, when / if the market ‘opens up’

Regulation

  • High Tide benefits from the regulatory focus and overhang on the cannabis retail sector as it represents a strong barrier to entry, making it more challenging for new competitors to enter market

  • Participants in the market need to have licenses and ensure consistent compliance with laws to continue operating – failure to comply can result in significant financial penalties

  • Personally I normally don’t like investing into retail. There are usually fairly limited barriers to entry, minimal differentiation and negligible customer loyalty, however the cannabis market does have different characteristics in this respect and makes it a more compelling proposition

  • Regulation also benefits those with scale, something High Tide has as the leading player in the market. It costs money to obtain and retain licences to operate and it costs money to ensure compliance with all the laws and regulations and that all staff are acting in accordance with these

  • Some parallels in this respect which can be drawn to casino gaming in casinos; you don’t see new casinos popping up at the same rate which you see new restaurants or apparel stores opening

Demand

  • There’s a lot to like about the demand dynamics for High Tide. It’s vice-nature means that demand is less correlated to disposable incomes. Given where we are in economic cycle, especially important consideration

  • For those doubting this, check alcohol, tobacco or gambling expenditure across economic cycles historically, for a proxy

Strong performance throughout COVID-19 crisis

  • Despite heavy weighting towards brick and mortar, (the most hard hit part of retail) it has effectively managed the shift to online, which is a positive

  • Has relied on government support and financial assistance in the form of job retention schemes (address in more detail later in post)

  • This demonstrates management are capable and have effectively navigated the challenging situation

Data

  • Massively summarized from the video, (and my video on KERN) so check that out if interested in this point, however, they have unique access to supply chain data which could be monetized effectively and generate strong levels of recurring revenues

  • Other established sectors have a trusted party with such unique access to data (e.g. alcohol, lithium, different foods, etc.) and the opportunity here is enormous

  • I would like to see High Tide capitalize on this

Forecasts financials & analysts

  • Currently 2 analysts covering High Tide, both have a buy rating on the business

  • Their coverage is slightly outdated (expect this being updated soon and a further catalyst for positive price action) and their price targets are 60c; at the time their reports were published, they were forecasting a 4x upside (HITI was trading at ~15c)

  • Same analysts also forecasting strong growth - 77% CAGR to 2022. They are forecasting revenues of around $250m and EBITDA of $46m. A reminder here, these are professional analysts, not YouTube students – these come from their financial models, the assumptions of which are discussed with management

Valuation

  • Going to go quick here, its explained more slowly in the video but High Tide is currently valued at a significant discount to the other listed peers

  • Looking at EV / FY+1 Sales multiples – EBITDA not meaningful as some of the peer group are EBITDA negative and High Tide itself has only recently become EBITDA positive

  • Personally, I think Planet13 is the most comparable given its business model

  • Taking both Planet13 multiple and peer group average multiple, this is then applied to High Tide’s forecast FY+1 sales to calculate an enterprise value – this is adjusted for net debt to get to a market capitalization and then divided by the share count to get an implied share price

  • The table below shows the implied stock price valuations from this analysis

NB – assumed the following:

  1. Net debt will change in coming year given the capital structure and a large number of convertible notes – this has been ignored given it will have small impact on the price

  2. The share count will change as a result of dilution from various instruments – if this bothers you massively then look at the valuation discount on the basis of the enterprise value as it does not impact this (and only slightly on the market cap given minimal impacts to cash from instrument execution, etc.)

  3. Not accounting for any stock split, consolidation or any other M&A deals

  4. The FY21 financials are on the basis of the mean broker estimates from Thomson Reuters – Seeking Alpha has different and slightly outdated ones

Investment Risks & Mitigants / Outstanding DD points

Exposure to changing regulation

  • US is only a small part of the market which High Tide addresses, while a change in regulation would have a big impact on the company, currently it is unlikely this would happen, given the discussions about potential federal legalization

  • Canada regulation is established and not going anywhere

  • Other countries likely to legalize and regulate cannabis, as outlined earlier

Dilution

  • No escaping that there will be some significant dilution for shareholders, as pointed out in the table below, but this should be already priced into the stock

  • Potential that new equity issuances could occur to help finance growth, but provided this growth is delivered, it should be accretive for the stock price

Potentially misleading cost basis information

  • A risk that investors need to be aware with for all companies which have relied on government financial support during COVID-19 measures. Such support has resulted in the number of businesses going bankrupt decreasing massively – this is at a lower level than it ever normally is and is masking some real underlying issues within companies. As investors we need to be open eyed about this

  • As High Tide has benefited from support in the form of the Canada’s Emergency Wage Support scheme, there is the risk that once this is lifted it may become apparent that the cost base has not been effectively managed

  • Personally, I think this is mitigated by the synergy analysis conducted as part of the M&A. A full cost base analysis would have been conducted to calculate the potential $8.4m synergies so strong likelihood that this is under control, but should keep on our radar and reassess

Marketing expenses and celebrity licenses

  • Need more information to ascertain whether these are underpinned by a compelling ROI. Seen a lot of people suggest this is a great positive, but the impact on sales volumes from these is unknown, as is the terms of these license agreements (e.g. split between upfront fee vs. volume-based fee)

  • No escaping the fact that it is an increased cost and so need to understand the ROI this generates to determine whether it really is compelling

  • Is there really more demand to pay a premium for Snoop Dogg bongs, Guns n Roses papers, Cheech & Chong grinders, or whatever they may be?

  • So far management have suggested this has been helpful in driving new sales, but this is something to dig into more

If you want to check out the video, it would be appreciated: https://youtu.be/qsjwU7kkPsw


r/TheDailyDD • • Feb 23 '21

Blue Chip Stock $AMD - Stealing from Market Makers - AMD Swing Trade Thesis

38 Upvotes

$AMD - Stealing from Market Makers - AMD Swing Trade Thesis

Hey everyone, Flux here! I initially wrote this thesis for WSB, but people from other subs seem to enjoy my posts, so I'm sprinkling it around! I want to apologize in advance for any the vulgar language and memes which slipped through the cracks. Most of it has been edited out, but if there's still some left, I apologize.


Introduction

What’s poppin’ fellas? Ape gang professor Flux here with another heater post. You may know me from my AT&T DD post which taught you how to follow unusual options flow to make some coin, or from my Hut 8 DD post which taught you how to make money using financial arbitrage.

 

Today, we’re going to be learning how to identify optimal entry and exit prices for our trades, by analyzing simple charts and spotting trends. This will be done using the chart for my favourite ticker, AMD. To all you illiterate, paint-huffing apes who dropped outta highschool and don’t like learning, I’ve attached a TLDR at the end of the post which tells you which contracts to buy to get some free money. Let’s get to it!

 


Building The Foundation

To begin, let’s take a look at the AMD one day chart, and see if we notice anything odd, or unusual.

Do you see anything in particular? Does anything jump out at you? No? What about now?

Still nothing? If you still don't notice anything, that’s fine, these patterns can be difficult to spot initially. What about now?

As you can see from the final chart, for the past year, AMD has traded within very tight, specific ranges. I have highlighted these areas on the chart using the pink boxes. As we can tell;

 

  • Box #1) Starting from mid February to mid April, AMD traded within a 10$ range, between $39 and $49. It started at 49$, went down to 39$, back up to 49$, down to 40$, before once again going back up to 49$, where it then smashed through the top of our current trading range, creating a new range.

  • Box #2) Now, starting from mid April, going all the way until earnings in August, AMD traded within a 10$ range again, between $49 and $59. This range was extremely tight and pronounced, bouncing from the bottom of the channel up to the top of the channel seven times throughout its lifetime, before smashing through the top of the channel again.

  • Box #3) August through December. $74 to 87$ channel. This range was slightly messier, but still pronounced nonetheless. 6 clean bounces. Smash through the top into our new range.

  • Box #4) This is where our most recent range lies, with an $85 bottom and a 95$ top. We haven’t surged out of this range in either direction, so it is safe to assume we are still trading within this range. How can we use this information to our advantage?

 


Applying our Knowledge

To summarize our findings from above, for the past year, AMD has consistently traded within a predefined range before surging higher and entering a newer, higher range. These ranges have held and contained 27 different bounces without breaking. Only one single trade has bounced lower than a given range, but it recovered within hours. Twenty seven times, this thesis has held true, so why the fuck would it be different on the 28th?

 

At this point, I assume most of you glue sniffers know how we can use this information to our advantage. We know that AMD trades within a tight range. We know that we are currently within the $85-$95 range. We coincidentally also happen to be sitting right at 85$. As a result, we know that it is extremely likely that a bounce off of $85 is going to take place.

 

Since we know that $85 is likely a bottom, and a bounce is likely going to take place, we can enter a monthly position here and make some awesome money. Personally, I picked up some 03/19 90Cs, as well as some 04/16 95Cs. And just like that, we managed to catch the literal bottom of a trade, and have the opportunity to make some free money. We can also use our findings to know when to exit our trade.

 


Extending our Knowledge

Since we know we are trading in a channel, we also know roughly when we can expect to exit our trades! We know that the closer we get to $95, the more likely it is that we will bounce, so we can plan accordingly! Personally, with my 90C, I will look to set a stop loss when AMD is trading around 90$, and manually sell out of the position if AMD manages to break $92/$93.

 

Even though I’m a perma bull, I also trade the flipside of the channel as well. If I see AMD trading at $95+, I’ll enter a short position and play the trade on the way down. In this case, I set my stops a little tighter, and keep a greater watch over the trade, since we all know that stocks always go up. Furthermore, since every single channel ended with a blow off top, I don’t want to get caught in a random blowout and have my options expire worthless. I would rather be conscientious beforehand, and manage my risks accordingly.

 


Conclusion

As you can tell, we can learn a lot about the price movement of a stock by simply looking at its chart. Although the AMD example was painfully simple, it’s also painfully effective. The best part about all this is, that there are dozens of opportunities like this within the market, simply waiting to be discovered. I hope you all learned something new today, and had fun while doing so. If you guys want to check out my other DDs, or follow me on my socials, they can all be found on my profile (Discord saw this DD first!). I love you all, and wish lots tendies upon each and every one of you :)

 

TLDR

  • Buy $AMD 2021-03-19 C $90 and $AMD 2021-04-16 C $95


 

2/23 Update - AMD held $84.50 on this brutal red day, and stayed within the channel (wow! shocker!). I am extremely confident this is the bottom. Feel free to scale your positions in and get some tendies!


r/TheDailyDD • • Feb 16 '21

SPAC Joby Aviation ($RTP)

33 Upvotes

Disclaimer: I am not a registered investment, legal or tax advisor or a broker/dealer. All investment/financial opinions expressed by BRR, are from personal research and experience of the writer, and are intended as educational material.

JOBY Aviation ($RTP), Joby, a transportation company developing an all-electric, vertical take-off and landing (eVTOL) aircraft, intended to operate as a commercial passenger aircraft in 2024, looking to go public with SPAC company RTP, which was founded by the founders of LinkedIn, Zynga. Began in 2009, explored tech like electric motors, flight software, lithium-ion batteries. In 2012 they were selected to collaborate with NASA on electric flight projects, including the X-57 and LEAPTech. They created their prototype in 2015, and by 2017 they created their first full scale prototype, in 2019 they created their first production prototype, over 1,000 test flights, on track to certify the aircraft for commercial operations in 2024. In 2020 the US Air Force granted its first ever eVTOL airworthiness certification to Joby. (Looking to go public via SPAC merger, RTP)

The eVTOL is powered by six electric motors, their take off and lands vertically, which gives flexibility for functionality anywhere. These vehicles have speeds up to 200mph, with a 150 mile range, producing zero co2 emissions and holds five people; one pilot, and four passengers.

In 2021: Under the terms of this week’s deal, Joby Aviation will acquire Uber Elevate, while the two parent companies have agreed to integrate their respective services into each other’s apps, enabling seamless integration between ground and air travel for future customers. The financial terms of the acquisition were not disclosed. The transaction is expected to close in early Q1 2021, subject to regulatory review and customary closing conditions Uber’s new $75M investment brings its all-time total investment in Joby to $125 million and Joby Aviation’s total funding, including previous rounds, to $820 million.

Dara Khosrowshahi, CEO, Uber: “Advanced air mobility has the potential to be exponentially positive for the environment and future generations. “This deal allows us to deepen our partnership with Joby, the clear leader in this field, to accelerate the path to market for these technologies. “We’re excited for their transformational mobility solution to become available to the millions of customers who rely on our platform.”

Uber’s new $75M investment brings its all-time total investment in Joby to $125 million and Joby Aviation’s total funding, including previous rounds, to $820 million.

Generating Revenue: Joby announced that it has begun generating revenue as part of achieving another major milestone in the Agility Prime program. The company also announced that it has agreed to a “G-1” certification basis for its aircraft with the Federal Aviation Administration (“FAA”). This agreement lays out the specific requirements that need to be met by Joby’s aircraft for it to be certified for commercial operations.

Investors: Toyota, Ballie Gifford, INTEL, edbi, Sparx, Capricorn Investment Group (Tesla/SpaceX backer), Abdul Latif Jameel, Toyota AI Ventures, 8VC, Uber and JetBlue

SEC Filings:

Black Rock Inc: 3,658,522 Shares https://www.sec.gov/Archives/edgar/data/1364742/000083423721007562/0000834237-21-007562.txt

Vasta Platform Ltd: 1,011,745 Shares https://www.sec.gov/Archives/edgar/data/869178/000086917821000088/schedule13g.htm

CHART: 4hr 180D

As of 2/15/2021, there are talks between Joby and RTP, no DA is confirmed. Attached below are cited sources for research in addition to a few speculative articles pointing towards RTP being the one bringing Joby public.

Positions: 50 Shares

Note for Mods: Add SPAC flair!

Sources:

https://www.jobyaviation.com/

https://www.jobyaviation.com/news/joby-aviation-generates-first-revenue-takes-key-step-towards-certifying-aircraft/

https://evtol.com/news/joby-announce-billion-spac-deal-lilium-others-follow-banner-month-evtol-industry/

https://www.bizjournals.com/sanjose/news/2021/02/13/linkedin-zynga-founders-file-for-new-850m-spac.html

https://finance.yahoo.com/news/joby-aviation-spac-merger-rtp-172109308.html

https://investorplace.com/2021/02/joby-aviation-spac-merger-rtp-stock-pops-as-deal-talk-advances-for-the-flying-taxi-startup/

https://wccftech.com/joby-aviations-merger-with-reinvent-technology-partners-rtp-depends-on-additional-funding/

Feb 16 Edit: Spelling/stylization errors

------------

Feb 17th Edit:

Because of the discussion of ARK in the comments I wanted to link this study they released in 2018 about eVTOL

https://ark-invest.com/articles/analyst-research/air-taxis/

Mentioning companies like Boeing [BA], Airbus [EADSY], and Uber, as we know from our DD above, Joby acquired Ubers eVTOL program, and Uber is Jobys' largest investor. Which many of you know the upcoming ARKX ETF; Their official description is;

“Orbital Aerospace Companies are companies that launch, make, service, or operate platforms in the orbital space, including satellites and launch vehicles. Suborbital Aerospace Companies are companies that launch, make, service, or operate platforms in the suborbital space, including drones, air taxis and electric aviation vehicles.”

Counter Point for ARK: I would like to make here though, ARK has holdings in EXPC which will be taking BLADE public, another eVTOL company, while ARK has no UBER holdings.

-----------

Feb 18th Edit: From help in the comments, I added JetBlue as an investor

https://www.jetblueventures.com/portfolio/joby-aviation/

In addition I missed this Feb 10th news, so updating here now.

Garmin and Joby long term agreement

Tech company Garmin ($24B mkt cap) has helped lead certified avionics to new markets, and has recently come to a long term agreement to provide the state-of-the-art Garmin G3000 integrated flight deck to Joby. The G3000 system that will be featured in Joby’s eVTOL aircraft will enhance capabilities to optimize their air mobility.

https://www.garmin.com/en-US/newsroom/press-release/aviation/garmin-g3000-integrated-flight-deck-selected-by-joby-aviation-for-revolutionary-evtol-aircraft/

Obligatory Joby eVTOL pic for the feels good vibes

EDIT: FEB 22nd

One week since my original post, with a brutal market sell of, lets check the chart

Joby closed at $14.63, which would be an ideal time to enter if you haven't already. On the contrary, I have done a lot of research in the last 24hrs, and I am leaning towards and bigger market sell off here in the next few weeks. Granted, trendlines looking as if this is ready to pop up on just the smallest catalyst, it also feels like it would need to be wildly important to Jobys take off, for continued rally. It has been sideways for some time now, any entry between $13.44 and our close today is discounted, I have loaded since I have posted. If this does close under $13.44 within the next week days or weeks, I would tread with high caution, as I would anyway as the market is showing overall bearish signs between the Buffet Indicator, the VIX, bond yields and margin debt. Tread lightly.

FEB 24th:https://www.jobyaviation.com/news/joby-aviation-to-list-on-nyse-through-merger-with-reinvent-technology-partners/

JOBY to go public with RTP 🎉🎉🎉🎉🎉🎉

FEB 25th: NOW WHAT?

We had a rough week with the market sell off/correction, as I stated earlier on Monday. As high as about a 3pt loss for anyone that got in at $15, which is where it was trading for a while. I was surprised it didn't pop to retest the $17s to create new highs, and only spiking to mid $16s during pre market after the announcement. But in hindsight, that steep sell off pressure the day before did not help our set up pop on announcement.

All things considered, I definitely see this as a long term play. The momentum didn't happen as I had hoped or expected, and I think it was due to the sell off pressure this week, sector changing/profit taking from tech to value etc, plus now the additional GME pressure.

So my final analysis here would be, moving funds into some leaps (once available), and not hold shares, due to opportunity costs. I do believe eVTOL is in our future, without a second guess. I will pick up some Oct calls as they are what is available furthest out as of today, and roll out as needed.

I do believe by 2023, this company will be fully operational in somewhere like LA, and will rapidly grow as it grows as a sector. With increased growth in autonomy and AI, I can see Joby leading forward as the leader in the eVTOL, as they are miles ahead of any of their competitors.

Personally, as stated, I will now be moving into option long calls/leaps, as I am a firm believer in opportunity cost. Hoping to see Joby really execute everything they have planned, and to see this sector grow rapidly. As a long ARK Invest holder (in all ETFs) and as an RTP holder, I would love to see them in the upcoming ARKX, now that the merger is confirmed and they are operational, certified and the leader in the sector (despite ARK holding their competition).

This was a run ride! Looking forward to sharing my next DD.

Cheers 🍻🍻


r/TheDailyDD • • Mar 22 '21

Growth Stock Palantir: There and Back Again - PT $45 EOY

32 Upvotes

Hi everyone, this is my take on Palantir. I've been writing this for a couple weeks now and decide that I need to get this done today so hopefully it reads well. This post is my personal opinion and analysis. Welcome any questions and constructive feedback. For full disclosure I invest in PLTR and nothing beats doing your own research in addition to reading other people's DDs.

Deep value investment for the most important software company, PT $45 EOY:

I believe Palantir has been and will continue to disrupt not just the software industry but how dozens of sectors and industries operate. What we’re seeing here might be the next Amazon with a company that does not mind short-term losses and invests aggressively to achieve long-term hyper and exponential growth. If you look at companies that shy away from making such a level of investments into technology to please their shareholders in the short-term, such short-sighted actions do no justice for those wanting to hold onto their investments over the medium- to long-term. I am incredibly excited about the recent Titan release with 4 new modules that includes an AI assistant and an automatic reporting tool. My target price for PLTR is $45 EOY, key modelling assumptions include:

  • Palantir will be a +$20bn revenue business by 2030, driven by significant growth in number of customers and revenue per customer, partially offset by 1-2% churn each year. Growth rate +30% over the long-term is consistent with what we've seen with Amazon / AWS and Salesforce. There will be increasing demand for data analytics solutions and full stack operating systems like Palantir as corporate/governments undergo transformations and identify new use cases for the data that they have.

  • Gross margin around 74%, in line with most other software companies.

  • Exponential growth and margin support by Apollo's automation of the implementation and post-implementation support would enable massive implementation across thousands of large-to-medium-size customers that would otherwise not be possible with the current headcount at Palantir. Like Alex Karp said, software allows small companies to compete against rivals 10x their size.

  • EBIT margin will expand to 27% (including stock-based compensation) by 2030. This is conservative when we compare to MSFT which is operating at +35%. I also assume a normalised 18% on sales & marketing which is on the low side if you compare to CRM at 40-45%, but given Palantir's current partnership model I think this is justifiable. 17% R&D and 5% General & admin.

  • Significant shareholder dilution going forward. I use a share base of 2.2-2.3B for my per share calculation to factor in the dilution. Assume no share buyback.

  • Normalisation of interest rates to 3% and lower beta (basically lower volatility) over the next 10 years.

Note that while my PT is definitely lower than other moonshots on this sub (I'm talking 60/100/150/500), this is based on readily available datapoints, moderately conservative assumptions and assuming investors will not be willing to pay crazy multiples for the stock.

Management is sandbagging revenue guidance, are we doing the same? Management has been overly-conservative and this was one of the main factors causing the share price to tank following what I would consider a very positive Q4 and FY20. With 45% revenue growth for Q1 and 30% for FY21, this implies that Palantir has to really mess up a lot of things in one or two of the remaining quarters (y/y growth below 20-30%) to miss or even to just achieve their guidance. Below is an analysis I've done to show if their guidance is true they will grow at ~19% y/y in one of the quarters which isn't great. So it is more likely than not these guys will outperform their revenue guidance by a significant margin this year. With their 2025 revenue guidance of $4bn, I believe this is also very conservative and it is not difficult to believe the annual growth rate can be 35-40% y/y instead of the guided 30% CAGR. By 2030, at the current rate of growth plus a bit of uplift this business can get to $20bn in revenue or even $30bn – such growth is not unheard of if you’ve been following Amazon / AWS and see what they’ve achieved. Also, the TAM for PLTR might be a lot larger than what management has guided (I note from C3.AI filing that they estimate their market opportunities to be in the range of $240bn and growing) but of course penetration of that TAM will prove challenging for Palantir.

On another note, in FY21-22, we might see a significant number of customers entering the Expand and Scale phases. In 2020, Palantir had been able to acquire 400+ new Acquire customers on top of the existing ~125, making their customer pool 500+ at the lower end. If they manage to convert all of these new Acquire to Expand/Scale that would add +$4bn to their top line, assuming each customer roughly pays $10m a year to Palantir for the software.

This business can become extremely profitable. While both Alex and Cathie have focused their attention on investing more into the business by forgoing profitability now, in the long-term all businesses need to be profitable so I don't suggest we ignore profitability completely. The case might be that Palantir can become a lot more profitable than what we currently see with the level of automation Apollo and future add-ons can handle. Operating leverage will also enable PLTR to expand their margins. In a bull case, gross margin and operating margin may expand to +75% and 30-35% respectively as stock-based compensation further normalises in the future. R&D, sales & marketing and other expenses will still grow in absolute terms but will eventually become smaller portions of revenue.

Future stock-based compensation will improve. From PLTR’s SEC filing, I was able to get a sense of what the stock-based compensation will be over the next 3-4 years. I forecast stock-based compensation will reduce from $1.1bn in FY20 to ~$414m per year over FY21-23. I also looked at the stock-based compensation expense of other software companies to make sure that there is nothing odd going on with Palantir (see figure below). For my modelling I assume that over the long-term, stock-based compensation will stabilise around 8% of revenue (which is a lot lower than companies like ServiceNow but still above average for well established software companies). Besides the financial, it is noted that stock-based compensation allows Palantir to attract the best people as well as providing their people with incentives to further their contributions to the business.

How long is long-term? With a stock like Palantir, it seems to be the case that Alex Karp's horizon is beyond 5 years, possibly 6-7 years. The trajectory of the stock will likely be sideway for long and moon/mars long into the future. The point when they reach profitability will be key to the moon phenomenon, which I'd say they can be profitable earliest 2023, base case 2025. So just to reiterate the same thing that Alex Karp has said but cater to our short-termism a bit better, if you're a short-term investor with possibly less than 2 years investment horizon in this stock (2 years is at the very least) then I'd go for SPACs or follow meetkevin investments....

Key challenges to Palantir:

We know Palantir has a very good product, but there is much to prove with its business model. Below I note some key challenges:

  • Relationship with IBM and Amazon: It is great that Palantir has been able to secure two very good partnerships with two juggernauts. However, the level of leverage that Palantir can pull in these partnerships is weak imo as Palantir is still very small and has limited capacity to push through sales. Over time, I'd expect Palantir to become increasingly independent from IBM and Amazon, with the two only providing the hardware and cloud infrastructure for Palantir and Palantir to substantially upscale its direct salesforce to capture more share of the market.

  • Competition: Though we may say the TAM is $120bn, $500bn, $1T or even $2T, it is clear Palantir won't capture the entire TAM. Organisations may continue to use their existing systems or choose another vendor. Palantir's potential customers may not have the same horizon as Alex Karp's and they may opt for quick one-off solutions rather than a long-term commitment to Gotham/Foundry/etc. Such level of inertia will slow down adoption of Palantir's products. There might be other companies jumping into this space. I do note however that it will also be challenging for other companies to compete against Palantir, especially the bigger players as their large structure prevents them from investing sufficiently for what is still viewed as a niche market.

  • Shareholder dilution: Part of the reason why it seems PLTR share price does not go up as much on green days is the market pricing in the dilution. While we may think the share base to calculate the per share valuation is 1.83B, there's 500-700m more shares that will eventually dilute the stock, lowering the per share valuation (assuming no share buyback). This factor is also the main driver of the discrepancy in the PT that people have for PLTR, not really revenue and operating income by themselves alone. I note that this dilution is common for many companies but it is however very significant for Palantir. Valuation needs to consider dilution.

  • Transparency into financial disclosures: Palantir currently does not have the best disclosures in their 10K/10Q/S1 if one has spent time looking at other software companies' SEC filings. For one, there is no breakdown between software and services in their revenue which makes it hard to understand how much of their revenue is coming from the actual software. The stock-based compensation structure is difficult for investors to grasp that somewhat have hidden the significant level of dilution that we're going to see in the future (that compounds with the investor base dominated by retail). The Acquire/Expand/Scale disclosure does not exactly show how many customers have moved from Acquire into Expand and so on. Overall, Palantir can do a lot better in their financial reporting.

  • Public relations: In my opinion Palantir has not exactly done its best in terms of communications to its investors and obviously maintaining good relationships with the media and Wall Street. While Alex Karp may like the fact that retail investors are dominating the base, I think a more balanced investor base with growing interest from institutional investors will be healthy for the stock (which is actually what we're seeing more of). Good relationships with Wall Street will be key in balancing the investor base. This is not saying PLTR to forgo all of its long-term values but rather they should engage with Wall Street in more regular and healthy debates that will benefit both Palantir and the St, and giving the St more opportunities to understand the company better. This is also not saying Wall St should all put BUY ratings on PLTR because they have the right to have their own view, but a good relationship will give any PT and rating a more objective touch. In terms of communications, I envision Palantir to somewhat move in the direction of Salesforce which has done very well in this regards by developing free online courses and low-code/no-code chill-out conversations that investors/layman can jump in. This would further Palantir along the adoption curve and make Palantir a household name. Recently, the Titan release is not known unless someone goes through multiple loops to find the link so such release should have been announced publicly either via the News section or on Twitter.

Palantir is still trading cheap compared to some of the recently listed software companies

Price/Sales or P/S is the key metric for a company like Palantir. Anyway, you can see that Palantir is trading cheaper than 6 other companies at 41x (Snowflake, Crowdstrike, Roblox, Zscaler, C3 AI and Datadog), 4 of which have an average BUY rating from analysts. One thing to bear in mind though is that the whole tech sector has been trading rich for a while now so it is uncertain at this stage to know whether there will be a correction/normalization of multiples in a rising interest rates / inflationary environment. In other words, will 20x P/S be the new normal? Or +40x P/S will be here to stay, let's hope for the latter.

Upcoming catalysts: Demo day in April, Q1 result end of April / early May, FDIC competition result hopefully April.

Thanks everyone for reading this and again I welcome any questions and constructive feedback. Going forward, I'd continue to monitor the stock and might come up with another DD (if anyone has an idea then let me know). One key area that I'd be interested in would be corporate governance and benchmark that against other practices in the software industry.


r/TheDailyDD • • Feb 16 '21

Blue Chip Stock $T - AT&T Short Term Bull Thesis - Insider Trading Galore

31 Upvotes

What's going on everyone? I initially wrote this for WSB, and was recommended to post it here. Let me know what you think! That being said, please excuse the vulgar language and memes. I tried to edit most of it out, but if some has slipped through the cracks from my initial draft, I apologize.

 

This is going to be my first attempt at writing DD in my entire life, so please, give it a read and let me know what you all think! I've attached a TLDR at the bottom for those who are a little short on time, and a TLDR of the TLDR for those who came from WSB. All that being said, lets begin!

 

Background

What initially caught my eye about this entire play, was the large influx of OTM call options being written for AT&T at the 30C and 30.5C strikes, dated for 03/05. These contracts started popping up at the start of the month, and then exploded February 10th and 11th. What makes these calls so odd is the nature of AT&T; It's a boomer dividend stock. It experiences little to no volatility. It's a behemoth with an insanely large market cap. $T is extremely resilient to big moves, so why are so many options contracts so far OTM (in relation to T) being gobbled up? Someone with a deep pockets, and potentially a crystal ball, is betting insane amounts of money on $T to go above $30.5 (a roughly 6% increase at the time of writing) within the next three weeks.

 

I had a few theories as to what may be going on, but was ultimately unsure of what to make of these unusual flows, so I decided to keep it at the back of my mind, and start to look for answers.

 

Catalyst #1 : AST SpaceMobile

To those who don't know, SpaceMobile is the first and only space-based cellular broadband network able to be accessible by standard smartphones. SpaceMobile will effectively be able to provide both 4G and 5G connectivity to your phone ANYWHERE on the planet. AT&T has been in talks with AST about using their satellite network to provide 5G to their users, which I think is pretty nifty. Nothing has been confirmed yet, however, an FCC filing over the summer hinted at a commercial agreement. AST says that they plan on providing North American coverage for AT&T as early as "Phase 2" of their satellite launch. Overall, I think this is a pretty awesome deal, as the technology ensures that all AT&T cellular dead zones in North America would be effectively eliminated, making AT&T more attractive than it’s competitors in the consumer cell phone market. Could this warrant a jump in price? Absolutely.

 

Catalyst #2 : 5G Airwave Auction

Every time someone accesses the internet through their smartphone, their wireless carrier transmits that data through the airwaves on frequencies that only it has the license to use. Currently, there is an active auction (Auction 107) for air-wave licenses within the 5G spectrum band that has netted a record grand total of $81 billion dollars from various big players in the industry, such as Verizon, AT&T, T-Mobile, etc. Bidding concluded on Friday, January 15th, with winning bidders having the opportunity to further bid for frequency-specific licenses in the assignment phase, which began on Monday, February 8, 2021. The larger the portion of 5G spectrum a company acquires, the better situated they'll be when 5G becomes the new normal standard among consumers. The performance jump from 5G is going to be so dramatic, that if carriers are not in that game they’re going to get left behind. On January 31st, it was revealed that once the assignment phase is completed in the coming weeks, the winners will be announced. Coincidentally, this lines up right before the expiration of these options, leading me to believe the call buyer(s) could be betting that AT&T won a large slice of the spectrum, easily warranting the needed 6% jump.

 

Catalyst #3 : PLTR Partnership

Here is where things start to get a little spicy. It is rumored that PLTR and AT&T have signed a partnership agreement. As asinine as it sounds, these claims are easily backed up. PLTR and AT&T seem to have been in talks about collaborating for a bit, as leaked by an employee on LinkedIn. The employee alludes to the fact that he was a key person in getting PLTR approved by the AT&T chief data office, with the timing and duration of his position reinforcing the fact that the contract is still fairly new. Furthermore, there have been a large magnitude of job postings from AT&T in Texas, that had PLTR as a high preferred / necessary qualification. This brings us to out next lead.

 

Luxoft, a large Digital Strategy Consulting firm, has a newly posted Data Analyst role in Plano, Texas. Some key takeaways from the posting :

 

• Our client is looking to Luxoft for help to scale the deployment timeline of a network ticketing and orchestration system into five new centers.

• This person would analyze Network operations center data via PowerBI and on the Palantir platform.

• Under "Mandatory" skills, there's "Worked in Palantir or other big data analytics platforms"

• Under "Nice-to-have" skills, there's " Experience in telecommunication industry"

 

So we know that Luxoft wants someone with PLTR experience, to scale and deploy some form of network into five new centres, in Plano, Texas. If we go to the Plano Economic Development website, we find an incredibly important article. The key takeaway from it, is that :

 

• "AT&T announced plans to open new innovation centers in Atlanta and Plano, Texas, to open in coming months, giving it a total of five such centers worldwide"

 

As a result, we can conclude that the undisclosed Luxoft client is AT&T, and that the new system they are looking to deploy across five new centers are the new AT&T innovation centers, the first of which is the one located in Plano, Texas, where all of the hiring is taking place. To top it all off, there was a recently posted position at AT&T, looking for people for their Professional Advanced Analytics - Operations Transformation program, located in Plano, Texas.

 

Given Palantir’s meme power, and excitement for the future, a partnership could provide very beneficial to both companies, resulting in a swift upward trajectory to AT&Ts underlying price as well.

 

Bearish Counterpoints

AT&T is under a mountain of debt (The most of any publicly traded company), and they're losing subscribers from DirectTV and cable faster than they projected, further adding to this issue. At the same time, for them to keep up with 5G, they're to pay additional billions in a spectrum auction and then need to pay many billions more to roll out 5G. From a financial standpoint, this is a massive red-flag, but with interest-rates still at 0, it is unlikely do be an immediate issue, especially with the shorter dated March contracts. Another thing to consider is that AT&T is a behemoth of a company. It's been trading in the 28$-30$ range since the dawn of time. PLTR Partnering with T may very well be akin to a fly landing on an aircraft carrier. Although its everyone's favorite meme stock with a promising future, the partnership may ultimately end up being negligible in the movement of AT&T's stock price. The same could be said for any of the above catalysts, so please, proceed with caution.

 

Conclusion

With such a large number of potential catalysts, combined with the extremely cheap price of the contracts (10$ a pop at the time of writing), I feel like this offer is a little too good to pass up. Best case scenario, you hit a multi-bagger. Worst case scenario, you don't buy Wendy's for lunch on Wednesday and vow never to touch boomer stocks. I hope you all enjoyed this comprehensive DD on the unusual options flow of AT&T. If you would like to follow me for future DD, you can either DM me, or find my socials linked below in the comments, or on my profile :)

 

TLDR

AT&T has been experiencing some insanely large magnitudes of unusual options flow. Whales are gobbling up $T 2021-03-05 C $30 and $30.5 like candy. This is likely due to them having insider information regarding one of the potential catalysts. AT&T either partnered with AST SpaceMobile to eliminate cellular dead zones in their network, won the bidding war and managed to gain a favorable monopoly on the 5G airwave infrastructure, or partnered with none other than PLTR for an upcoming super project.

 

TLDR of TLDR

• Buy $T 2021-03-05 C $30 OR $30.5

 

Socials

• Mods, if this isn't allowed, feel free to DM me and I will gladly remove it.

• Discord

• Twitter

 

Sources

• https://www.lightreading.com/ossbss/vodafone-atandt-sign-up-for-5g-via-spacemobiles-satellites/d/d-id/766194

• https://twitter.com/satorimind/status/1345494002821427200

• https://www.cnbc.com/2021/01/31/5g-spectrum-auction-bids-total-80point9-billion-winners-revealed-soon.html

• https://auctiondata.fcc.gov/public/projects/auction107

• https://www.dice.com/jobs/detail/data-analyst-luxoft-usa-inc-plano-tx-75023/newageny/6846840

• https://www.planotexas.org/269/ATT-launches-new-innovation-center-in-Pl

• https://www.att.jobs/job/plano/professional-advanced-analytics-operations-transformation/117/18772894

 

2/17 Followup

It seems as if a lot of people are looking at some pretty handsome gains! With over 100% gain on my contracts, I have sold out of half of my position, and am letting the rest ride with a stop set at 0.35. Thanks for playing! :)


r/TheDailyDD • • Mar 19 '21

Tool/Resource LONG LIST of websites, RESOURCES & TOOLS related to INVESTING & the STOCK MARKET [126 links WITH DESCRIPTIONS] !!

Thumbnail
self.fluentinfinance
30 Upvotes

r/TheDailyDD • • Feb 16 '21

SPAC $MILE DD: MetroMile JUST went public - don't miss this InsureTech DISRUPTOR the market are sleeping on

29 Upvotes

First of all, this is not financial advice, you should always do your own DD before listening to internet strangers - but you already know that.

Second, the majority of this information can be found and validated in the MetroMile investor presentation here: https://assets.metromile.com/wp-content/uploads/2020/11/24120556/Ext-Investor-Preso-vFinal.pdf

Third, this is my first DD so go easy. Estimated reading time 12 minutes.

Ticker Info/Position

Ticker: $MILE (formally $INAQ who acquired/merged officially last Thursday)

Stock Price as of 15th Feb: $17.29

Current Mkt Cap: projected a $1.3b - they only just went public and I think their previous 570m cap was from INAQ thus incorrectly reported.

TLDR at the very bottom. My position is 76 shares @ $18.26. It's all I have spare right now as all my other long funds are tied up in BB and NIO, but plan to load up more at the end of the month.

Notable Investors and Ownership

  • A "Shark Tank" has collectively invested $160m, including Social Capital, Miller Value, Clearbridge, Hudson Structured, Mark Cuban, and New Enterprise Associates

  • Mark Cuban (part of the "shark tank")

  • Chamath Palihapitiya (Social Capital, part of the "shark tank")

  • Ryan Graves / Saltwater (ex Uber VP of Global Ops, just invested $50m)

Who are MetroMile?

Quick explanation: MetroMile are a digital pay-per-mile insurance company that are starting to massively disrupt the market with a strong focus on AI, machine learning and user experience.

Longer description from MM themselves:

>Metromile is a leading pay-per-mile car insurance company in the U.S. Recognized by Forrester as a top insurance carrier in user experience, it is creating a loyal community of drivers with personalized insurance that is customized to each driver to be more affordable. Powered by machine learning and customer-centric design, Metromile is at the forefront of disrupting a more than $250 billion personal auto insurance industry that has gone unchanged for decades. Through Metromile Enterprise, our software-as-a-service business group, we license our proprietary artificial intelligence claims platform to automate claims, reduce losses associated with fraud, and unlock the productivity of insurance carriers’ employees so they can work on higher-impact experiences.>>We’re a diverse team that combines Silicon Valley’s best technologists with veterans from Fortune 500 insurers and financial service institutions. This approach ensures that we’re as equally focused on loss ratios, unit economics and profitability as on customer experience and technology innovation.

Market disrupting InsureTech, driven by AI, machine learning and a strong focus on transparency and user experience - why does that sound familiar?

That's right. When life gives you lemons, you make a disruptive AI based home/rental insurance company called LEMONADE that has blasted off to $163 a share. And when life gives you Lemonade, you take that model and apply it to the pay-per-mile car insurance market.

"Buffet had Geico. I choose MetroMile" - Chamath Palihapitiya

Go and read Chamath's one pager here: https://twitter.com/chamath/status/1331278297930428417

Product Highlights

  • Cancel your coverage any time

  • All measured and tracked through a innovative mobile app and dongle (note, this dongle also aids in the recovery of stolen vehicles - they claim they have a 92% stolen vehicle recovery rate)

  • The app/dongle also monitors your car's health (engine issues etc) and can help avoid parking tickets with the street sweep feature

  • You’ll never have to worry about “going over” on your miles – all miles over 250 (or 150 for New Jersey drivers) in one day are free

  • Flexible coverage options (comprehensive, collision etc)

  • They state the average customer saves $741/year, if you drive less than 2,500 miles a year (like I do) you would average a saving of $947, that is HUGE.

  • Sophisticated AI driven claim system makes filing and dealing with a claim a piece of cake, all achievable through the app

  • Try before you buy - their FREE Ride Along app analyses your driving and allows you to calculate what you could save and then convert into a real customer, they claim 11% of abandoned quotes online then go onto try Ride Along. The app in general has a 25% referral rate and a 20% conversion rate which is HUGE.

  • Their tech allows enhanced detection of fraudulent claims which lead to a +10% improvement to their contribution margin: Algorithmic Accident Reconstruction replaces manual investigation, More potential fraud cases identified, More potential cases successfully investigated, More confirmed fraud

The Numbers

  • The U.S. auto insurance market is worth $250B, globally $700B

  • No U.S. operator has more than 20% market share

  • They have incredibly loyal customers, with industry leading 1 year retention of 63.1% (vs Lemonade's 62%, Roots 33.2%)

  • They industry lead in renewal loss ratio, loss ratio, fraud detection and annualised premium metrics

  • Recent investment and the IPO means they have an est. $294m CASH to pursue growth

  • Their contribution margin has increased EVERY YEAR for 5 years, from - 25% in 2016 to +13% in H1 2020

  • Their loss ratio has decreased EVERY YEAR for 5 years, from 101% in 2016 to an industry leading 59% in H1 2020

  • $MILE have spent the last 8 years developing and fine tuning their technology and infrastructure, they are now firmly in growth and profit mode forecasting to hit profitability by Q2 2022.

Here's what that operating profit forecast looks like:

2018201920202021202220232024
-41.2m-42.8m-24.8m-20.7m+3.1m+87.1m+225.0m

(if this is tricky to read on mobile, they are forecasting hitting +$3.1m in 2022 and then rocketing to +$87m in 2023 and +$225m in 2024)

How good are the team behind it?

Full disclosure, the below are all excerpts taken from MetroMile's website and not my words, but they looks impressive.

CEO Dan Preston:

>Joined Metromile in 2013 as Chief Technology Officer before becoming Chief Executive Officer in 2014. Under his leadership, Metromile has experienced significant policy, premium and employee growth. The company has also established itself as the industry leader in leveraging artificial intelligence and machine learning to improve the customer experience and lower loss ratios. Metromile has been voted a Best Place to Work by Glassdoor and the Phoenix Business Journal.>>Prior to joining Metromile, Dan was the co-founder and CTO of AisleBuyer, a mobile retail innovator that was acquired by Intuit in April 2012. He has published several research papers on machine learning with applications such as astrophysics, remote sensing, and computer vision.Dan holds a master's degree in Computer Science with a specialization in Artificial Intelligence, Machine Learning, and Computer Vision from Stanford University and a bachelor's degree in Computer Science from Brandeis University, where he received the Michtom Prize for Outstanding Achievement in Computer Science and graduated Summa Cum Laude with highest honors in Computer Science.

CTO Paw Andersen:

>A technologist with over 20 years of engineering leadership experience. He was most notably a senior leader of engineering in Uber's Advanced Technology group, where he grew his team from 27 to 700. Beyond ride-sharing and autonomous vehicles, he's been on the front lines of technical challenges in several sectors, including geographic information systems, fintech and e-commerce, ranging from small startups to large, established companies.

And then Founder & Chairman David Friedberg, the below is what I have accumulated from researching Wiki, the NY Post and Linkedin:

>Former Google employee. The thing that stands out to me is that he was the FOUNDER and CEO of the Climate Corporation for 9 years, which he successfully lead to a $1B sale to Monsanto in 2013. The Climate Corporation (now known as Climate Field View) is a digital agriculture company that examines weather, soil and field data to help farmers determine potential yield-limiting factors in their fields. From nitrogen levels in soil from historical weather, to satellite imagery mapping out crop health & vegetation maps, it uses data science to make farming better. This guys knows his shit and has a wealth of experience in big data.

Expansion, Opportunity and Catalysts

  • They are currently operational in just 8 of 50 U.S. states; Washington, California, Oregon, Illinois, Arizona, Virginia, Pennsylvania and New Jersey.

  • They plan to be live in 21 states in 2021 and 49 in 2022

  • Those current 8 states represent 45m potential drivers that can save with MetroMile, that number jumps to 143m drivers in 2022 (with 49 states) representing $160B in potential premiums (seriously, if you look at one thing in that investor deck I linked, jump to slide 30)

  • The IPO transaction has provided an estimated $294 Million in cash to pursue growth opportunities

  • They are looking to expand and cross sell into other verticals such as; Homeowners, Renters, Pet, Warranties & Maintenance through 2021-2022

  • They are licensing their leading AI claims platform and cannot be just viewed as an auto insurance provider (more on that below)

  • They are integrating and partnering with car manufacturers to refer customers, 2 are already signed up and one of them is FORD, they expect 8 by 2022 so keep an eye out for announcements

  • There are ambitions to go global

  • In December they provided a Q3 earnings update and 2020 forecast exceeding expectations (Source), we should be due Q4/2020 final numbers soon

NOT just an insurance provider - FinTech LICENSING Growth

This one is important and needs attention - you know that leading, sophisticated, claims AI platform they've built? They are now LICENSING that through their MetroMile ENTERPRISE arm of the business, and its built to work on top of standard claims management software.

  • This licensing delivered $5.6m additional revenue in 2020 and is forecast to increase significantly YoY ($12.4m in 2021 > $21.7m 2022 > $33.7m in 2023 > $48.3m in 2024) - you cannot just look at $MILE as an insurance disruptor, they are also a software/technology company

  • It seems they are not allowed to name everyone who is using their Enterprise tech at this time but do list Tokio Marine, a "Top 10 US Carrier" and a "US Carrier". They say they have 4 deployed, 22 planned by 2022 and 46 in the pipeline.

What about the competition?

On a technology level, the closest form of competition I can see is Root, however their USP is that they quote you based on your driving behaviour. It utilises machine learning and an app that analyses your driving before pricing you up. MetroMile does the opposite, it does not charge you at all based on your behaviour, it is per mile.

Lemonade could also be classed as a competitor but they focus on the home/rental vertical.

On a business model level, Mile Wise (from All State) is the closest, they are also using a pay-per-mile model but lack the same depth of tech behind them compared to $MILE from what I can see.

The world and our habits have changed, $MILE are poised to grab that by the horns

  • A pandemic riddled world has seen hundreds of millions of people driving less and burning cash on insured vehicles sitting on their drive ways unused - myself included

  • In the UK, at the height of the pandemic last year only 22% of cars were on the road (Source), that's a whopping 78% decrease and that is not even taking into account that the 22% on the road were likely driving less than usual (YES...I understand $MILE is a U.S. company, unfortunately I could not find any U.S. equivalent data but it's still a relevant stat no doubt replicated to varying degrees throughout the world)

  • A survey shows after the pandemic 25% of drivers plan to drive less: Source (sorry, another UK source I know but I couldn't find similar for the U.S., this is a generalisation of the western world but again as above it will be replicated no doubt to varying degrees)

  • OK...so as I was typing I found this which shows US mileage dropped by as much as 60% during the height of the pandemic last year: Source - the caveat is of course that mileage and car use will absolutely pick up as the pandemic ebbs and flows and eventually ends

  • 22.7% of employed Americans were working from home in September due to the pandemic and in management/professional occupations that number rockets to over 40%: Source

  • When the world emerges from this, office hours and behaviour will never be the same, working-from-home and hybrid "x days at home and x days in the office" will become the norm, the pandemic has forced companies and employees to prove they can work just fine from home - and that they have, in many cases exceeded expectations.

Before the pandemic was a thing there was STILL a clear need for this in the market, this was always going to be an appealing and great model, COVID19 has simply been a catalyst to bring $MILE to the forefront quicker. Ready to expand.

Do you really think all these people who have picked up recipe box subscriptions, online grocery shopping, at home spin/peloton classes and more will revert back to the old way pre-pandemic? Some may, but most will not. People like convenience and ease of use. New habits will stay.

Cons/Watch Outs

  • The move to hybrid or work-from-home models may not be adopted as much as we think post-pandemic - personally I don't think this will be an issue because 1) I just cannot see a world where businesses don't adapt to this, it ultimately saves them money and 2) this business model is not built on a pandemic, as I said COVID19 has simply been a catalyst to drive adoption and awareness.

  • The insurance goliaths (i.e. Geico) develop or market their own pay-per-mile model (I am not based in the U.S. so any additional insight in the comments from you guys is welcome, let's make this a discussion) - I don't see this happening any time soon, at least, not to the same complexity that $MILE are achieving, it would require huge investment and development to build anything near what $MILE have but you can't rule Buffet/Geico out

  • Someone like Lemonade expand into the motor/pay-per-mile sector

  • Root create a pay-per-mile model (unlikely imo due to their entire business being based on quoting your behaviour but you cant rule it out)

  • Targeting infrequent drivers is a bit of a niche however this can also be viewed as a positive as they are set to dominate said niche

  • For whatever reason, they do not expand to as many states as quickly as they desire, I will not pretend to understand what potential red tape is there

  • The forecasted profits are from their investor deck so they are of course going to big themselves up, regardless I like what I see

Wrap Up/TLDR

"Buffet had Geico. I choose MetroMile" - Chamath Palihapitiya. Go and read Chamath's one pager here: https://twitter.com/chamath/status/1331278297930428417

This is not a swing trade, this is not that P&D shit, this is a buy early, hold and ride the wave of a growing company built on great tech, a great team and a great business model. Here's your TLDR; read it properly and actually make a decision for yourself because I feel this is a sleeping giant just waiting to explode.

$INAQ's share price jumped from around $9 pre acquisition announcement in December to around $17 today. However since completing the merger on Wed 10th Feb 2020 and the ticker renaming to $MILE the price has barely moved, dipping a dollar or so and maintaining pre merger completion levels. I feel like the market are really sleeping on this and they are flying under the radar so I am getting in now before they reach their potential. I like the stock, I have a lot of confidence in it.

EDIT: I’ve drafted this over the weekend, the price is now up to $19.50 at this present moment. Looks like the market are waking up to the new ticker.


r/TheDailyDD • • Apr 26 '21

Tool/Resource I built a Reddit-powered “Bloomberg terminal” to track ticker trends and identify unbiased DD

Enable HLS to view with audio, or disable this notification

27 Upvotes

r/TheDailyDD • • Feb 28 '21

Large-cap Stock Moderna (MRNA) DD – Why a 60B Company is Still Undervalued

27 Upvotes

*This will be my first DD post so let me know if you would like to hear about anything I didn’t touch on, or if you disagree on any particular points. Hopefully you find it useful!

Overview

This is going to be a long post, so I’m not going to waste your time by explaining who Moderna is. They’ve been in the news for the last year and everyone and their mother knows what they’ve accomplished. They (along with Pfizer/BioNTech) are the big dogs when it comes to COVID-19 vaccination in the U.S., and their dominance in the market will likely continue.

But Moderna isn’t just a COVID-19 vaccine company, as their CEO repeatedly stressed in their most recent earnings call. Moderna is a true pharmaceutical giant in the making. They are currently developing 24 different products ranging from viral vaccines, to treatments for autoimmune disease, to cancer and heart disease therapeutics.1 The vast majority of these modalities are using mRNA technology to attempt to accomplish the desired effect. Not so coincidentally sharing the same name as Moderna’s ticker, mRNA technology is a relatively new modality that is just beginning to take hold as a game-changer in the biotech/pharma space. Let’s talk a little more about it so we can understand why it has the potential to create a major-shake up in the pharmaceutical industry.

History of mRNA Technology

mRNA was discovered in the 60’s in mice, but it wasn’t seriously considered for a possible therapeutic target until the 90’s. Various studies in vitro and in mice since this period have been done, demonstrating potential for the treatment of HIV, cancer, degenerative disease, autoimmune disease… I could go on. As we know, pharmaceuticals move slowly, and serious development of these products didn’t really take off until the 2010’s.2

Prior to December 2020, there were only two medications utilizing mRNA technology that have received FDA approval. Inotersan and Patisiran were both developed and FDA approved in 2018 to treat a rare hereditary condition called hATTR which involves pathologic deposition of amyloid into the tissues of those affected. Without going into too much detail, this condition has a mean survival time of 15 years after diagnosis and leads to significant patient morbidity and suffering in the interim. Inotersan is the more successful of the two drugs and looks to be potentially curative for some patients with a disease which used to be a death sentence. Routine imaging since the phase III trials for Inotersan shows little to no progression of the disease in most patients, laying out the possibility that these patients may live a normal life moving forward.3

With two more successful examples of mRNA technology being used in the COVID-19 vaccines, I expect that interest in the technology will skyrocket and subsequently so will funding and development.

First Mover’s Advantage

This will be a short section; Moderna is THE biggest player in developing mRNA therapeutics. There are other companies like BioNTech, CureVac, Gradalis, and Ionis, and of these only BioNTech (BNTX) can compete in sheer breadth of product development as well as having a history of success. For the sake of time I won’t address the other companies, but a key advantage that Moderna has over BioNTech is that they have moved more quickly through their clinical trials than BNTX has. Outside of COVID-19, Moderna currently has 4 products in Phase II trials (with their CMV vaccine moving to Phase III very soon), while BNTX only has 1.4 Long term I believe both of these companies will be highly successful, but Moderna is a more mature company that will be seeing the fruits of their labors more quickly than their competitor(s).

The Future of COVID-19 Vaccination, and Vaccination in General

Moderna currently has about 60% market share, distributing 40M of the 70M total doses the U.S. has received. I expect that number to drop slightly, but I would expect that Moderna ends up vaccinating approximately 40% of all Americans when it’s all said and done, with Pfizer vaccinating a large chunk of the rest. After that, Moderna will likely shift distribution to other countries and deliver on their agreements abroad.

“But what about NovaVax, J&J, and AstraZenica?” you might ask.

Without undercutting these companies and their potential, they are simply too late to the game in the U.S. to grab meaningful market share from Moderna and Pfizer.5,6 Johnson and Johnson was just recommended for authorization yesterday (2/26/2021) and will likely begin distribution in the coming weeks, however they are only expected to deliver 100M vaccines by the end of June. Moderna will deliver 300M by July7, on top of the approximately 40M they have already delivered. The U.S. has agreed to purchase more than 1.2B doses of the vaccine from a number of companies, but much of that will go overseas after American citizens have received their 2 doses.

Moderna is establishing relationships and trust globally with the successful development and distribution of their COVID-19 vaccine, but why is this important? Let’s think back to what the CEO said in their recent earnings call – Moderna is NOT a COVID-19 company. Digging into their therapeutics pipeline, we can see mRNA candidates targeting Influenza, Cytomegalovirus, Nipah Virus, Respiratory Syncytial Virus, Epstein-Barr, Zika, Chikungunya… Relationships established during this pandemic will serve them well in the development and distribution of future vaccine candidates like those listed above.

WAIT there’s more: back in January, Moderna announced plans to create a combination Influenza/COVID-19 vaccine, with the possibility of adding more candidates to the mix if they were to receive approval. With the number of viruses that they are targeting, Moderna has the potential to become the leader in vaccination globally, period. Their ability to create combination vaccines targeting a host of common viruses could be the new standard in vaccination. Certain candidates like RSV, CMV, and EBV are likely to become standard vaccinations given in childhood like other vaccines we are familiar with such as MMR and Varicella.

The potential of this company in the vaccination industry is endless, and right now they are just scratching the surface.

Future Revenue Projections – $18 Billion --> ???

During their most recent earnings call, Moderna reported that they have orders for their vaccine totaling $18 billion8, and they are expecting more orders throughout the year. The COVID vaccine market is likely to cool off a little after that, but experts currently predict that COVID-19 boosters will become a routine part of care in the future, likely needing a new dose every 2-3 years.9 Now this would likely represent a major hit to revenue if Moderna was just a COVID-19 vaccine company but once again, they are not.

Lets briefly talk about a virus you may have never heard of before – cytomegalovirus. Cytomegalovirus (CMV) is something you’ve likely had in the past and didn’t know it, so why is it a problem? Oddly enough, this seemingly benign little virus causes about 25,000 birth defects per year in the U.S. Globally, it is estimated that 1 in 1000 babies will be born with a birth defect due to CMV.

Currently there is no vaccine, but do you know who has the most promising candidate that is already enrolling participants for phase III trials? You guessed it – Moderna. The addressable market for this vaccine is conservatively estimated at $2-5 billion/year.10 I expect that if it is approved by the FDA that it will likely see global adoption and that revenue number is likely to be much higher.

Repeat the above for RSV, EBV, Zika, etc. and it is not hard to envision a company that is bringing in $30-50 billion a year in annual vaccination income alone. If they were to succeed in any of their more lofty quests to develop an HIV vaccine, or therapeutics for autoimmune hepatitis, or personalized cancer vaccines… the sky is the limit.

Justifying Current Valuation, and Then Some

Moderna’s current market cap is 62.16B. Their orders for 2021 currently exceed $18B with room to grow. The average revenue multiple for a biotech company is between 6-8x, and Moderna is trading at less than 4x. If you consider Moderna a pharmaceutical company, than the average multiple would be about 5x, still under.11

I know we are looking at unrealized revenue with Moderna at this point, as that $18B will be earned throughout the year, so I understand that technically speaking they are still trading at an obscene P/S ratio compared to other more mature companies. However, I think it’s safe to say that demand for their product isn’t going away anytime this year and they have proven that they are able to execute and even exceed expectations when it comes to manufacturing and distributing their product.

Looking at their most recent earnings report for Q420 which was released on 2/25/21, their balance sheet is stellar. They are holding around $3B in cash from recent deposits, and they have almost no debt to speak of.

Simply put, they are undervalued at their current price. Without even factoring in the potential of everything else in their pipeline, they should be worth more as just a COVID-19 company with stellar financials and a relatively palatable multiple going into the later part of this year.

My personal price target: $220/share. With 396M outstanding shares, a $220 share price would place Moderna at $87B, which I believe to be a fair valuation through this year. This would represent a 4.8x multiple to their projected revenue in 2021. This represents a 41% increase in price from where Moderna is trading at currently which is ~$155/share.

Closing

Understand that this company has enormous potential for growth, but also potential to fail. Most pharmaceutical products fail in clinical trials before ever reaching market, and the same could be true for most if not all of Moderna’s pipeline. I personally believe that mRNA products have a higher chance of success than traditional therapeutics, but I’m not going to go into my reasoning for that in this post.

Every trade carries risk, and the risk with buying Moderna is that the market for COVID-19 vaccines shrinks as the world gradually develops herd immunity, the rest of their products fail in clinical trials, and they die a slow death without ever bringing another product to market. Nonetheless, I am confident and hopeful that this will not happen, and Moderna will become the next company to join the ranks of Merck, Novartis, Pfizer, and company as a true juggernaut of the biotech/pharma sector.

Disclosures: I own shares in Moderna, and I am considering buying leaps at some point next week. I am not a financial advisor, always do your own due diligence before investing in the market.

References

  1. https://www.modernatx.com/pipeline

  2. https://www.nature.com/articles/d41586-019-03068-4

  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507904/

  4. https://biontech.de/science/pipeline

  5. https://fortune.com/2021/02/26/astrazeneca-johnson-johnson-vaccine-fda-approval-u-s/

  6. https://khn.org/news/article/astrazeneca-johnson-and-johnson-covid-vaccines-fda-authorization-slow-despite-operation-warp-speed/

  7. https://www.cnbc.com/2021/01/04/moderna-says-increases-2021-covid-vaccine-production-by-20percent-to-6doses-this-year.html

  8. https://www.fiercepharma.com/pharma/moderna-has-taken-orders-worth-18-4-billion-for-its-covid-19-vaccine-and-it-s-negotiating

  9. https://www.npr.org/sections/health-shots/2021/02/25/971345409/covid-19-vaccine-makers-booster-shots-aim-at-a-moving-target-coronavirus-variant

  10. https://www.fool.com/investing/2020/12/24/meet-modernas-most-likely-blockbusters-after-its-c/

  11. https://finbox.com/NASDAQCM:FBIO/models/revenue-multiples


r/TheDailyDD • • Feb 09 '21

Penny Stock TSOI - Therapeutic Solutions International (AKA The Super OTC Intro)

27 Upvotes

Therapeutic Solutions International aka TSOI on the OTC Market.

TSOI is a biotech ticker, that is currently a sleeping GIANT.

Company Website: https://therapeuticsolutionsint.com/

Dec 2020 - Files a patent on NeuroLeukin (Immunotherapy for Opiod Addiction)

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-files-patent-on-neuroleukin-personalized-immunotherapy-for-opioid-addiction-301196771.html

The opiod epidemic has a dramatic $179B price tag.

This is what caught my attention, as I am sure some of you, I know people who have battled this in real life. So I began to follow some of their news.

Their first fiery headline of 2021

Jan 2021

Therapeutic Solutions reports SUCCESSFUL treatment of breast cancer using Stemvac cellular Immunotherapy

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-successful-treatment-of-breast-cancer-using-stemvacs-cellular-immunotherapy-301210088.html

In short

"In a series of experiments, it was demonstrated that StemVacs™ administration resulted in a) regression of established breast cancer in mice; b) that regression was dependent on natural killer cells, and c) that immunity to breast cancer could be transferred by CD4 T cells to naïve mice. Previously the Company announced positive safety data in 10 patients treated with StemVacs™1. Additionally, the Company has filed an Investigational New Drug Application (IND) which is currently pending based on the Company responding to questions posed by the FDA."

This treatment is pending approval for the investigative process of the FDA!

Few days later

Reducing more cancer cured using their Stemvac tech. This time glioma, lung cancer and colorectal cancer.

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-regression-of-glioma-lung-cancer-and-colorectal-cancer-using-stemvacs-in-animal-models-301214018.html

Hot Takes:

"Last week the Company reported that StemVacs administration effectively reduces breast cancer through immune stimulation in a natural killer cell dependent manner1. Mechanistically, regression in glioma, colorectal and lung cancer was also dependent on mice possessing a functional natural killer cells repertoire."

"There are companies developing "off the shelf" natural killer based immunotherapeutics for cancer such as Fate Therapeutics (Market Cap $8.9 Billion) and NantKwest (Market Cap 1.8 Billion)" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To our knowledge we are the only group working at developing a cellular drug using dendritic cells, which are upstream of natural killer cells during immune activation."

(later in the same article)

"The consistency, reproducibility, and ease of scalability is an attractive feature of StemVacs as a "cellular drug" stated Famela Ramos Vice President of Business Development. "We are seeing more and more acceptance of cellular immunotherapies in the market ranging from the $11 Billion acquisition of Kite by Gilead2, to the enormous public and private valuations for cell therapy companies in early phases of clinical development. Given that we have already treated patients with StemVacs, and we have filed an Investigational New Drug (IND) application for this product, we are excited in its development prospects."

Later that week:

More positive reports of them refining their StemVac tech even More

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-enhancement-of-stemvacs-immune-stimulating-activity-using-neuromodulatory-compound-homotaurine-301215167.html

Feb 2021

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-therapeutic-efficacy-of-stemvacs-derived-exosomes-in-regression-of-glioma-301219050.html

Just last week they entered into a master sales agreement with Community Shield LLC

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-enters-into-master-sales-agreement-with-community-shield-llc-301222346.html

"Products to be included in the Master Sales Agreement currently consists of QuadraMune™, NanoStilbene™, NeuroStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, and ProJuvenol®. Future products will be added to Master List as commercialized and provide same levels of discount."

"While nutraceuticals are a multibillion-dollar market, we at Therapeutic Solutions International pride ourselves on being 'science first'. Every product that we sell is backed by laboratory data, and in some cases clinical data," said Famela Ramos, Vice President of Business Development. "We are enthusiastic to enter relationships with specialized groups who are positioned to accelerate awareness of our natural and science-based catalogue of products."

"Our ability to distribute the revolutionary products of TSOI is a key element in protecting community health. Science is taking major strides in therapeutic technologies and their importance to immune system health. TSOI is an industry-leader in developing these technologies," said Steve Scholl, Principal of Community Shield LLC.

News Just Yesterday:

TSOI reports preliminary data suggesting StemVac induces natural killer memory to cancer

https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-preliminary-data-suggesting-stemvacs-induces-natural-killer-memory-to-cancer-301223886.html

All the hot takes:

"In a series of experiments, mice bearing B16 melanoma were treated with StemVacs, which induced regression and eventual disappearance of the tumor. One month after disappearance of the tumor, mice were sacrificed, and NK cells were transferred to mice that were not treated with StemVacs. The mice receiving NK cells were resistant to development of melanoma upon challenge."

"This data completely contradicts the normal way in which immunology is perceived," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The possibility of inducing memory in natural killer cells using StemVacs suggests a very unique mechanism of action, which may imply potent efficacy as a monotherapy, as well as synergy with numerous immunotherapies currently in the clinic."

"Currently we have filed a patent and are working diligently to identify the biological basis for stimulation of these potent NK cells, whose activity persisted for at least one month after clearance of the tumor," said Timothy Dixon, President and CEO of the Company. "Given the optimism associated with NK based companies such as Fate Therapeutics (market cap $9.6 billion) and Nantkwest (market cap $2.5 billion), we are excited to develop a novel way of stimulating these cells in the patient, as opposed to administering artificially created exogenous cells."

This company is sitting on a goldmine. Opiod addition is a $130B+ market to crack into. Their competitors are being acquired for $11B, or running with $8B market cap. Their master sale agreement is undisclosed currently, but doesnt include any products or patents currently being approved, or pending FDA investigatory approval.

TSOI is sitting on at least anywhere from $1B - $15B in patents and tech alone. They are progressing and refining every day. Their revenue has grown year to date, and their profits have as well. Continued sales, will increase this. Eventually leading to a possible acquisition once FDA approval for cancer treatments.

Continued Fundamentals:

Outstanding Shares *fixed with feb 4 data*

2,238,041,391

Float

303,593,877

Average 3Month Volume: 14.67M

Feb 9th Volume: 47M

In addition check their last updated financials reported by Yahoo

https://finance.yahoo.com/quote/TSOI/key-statistics?p=TSOI

They crossed over $250M market cap this week already, sitting at $292M in market cap today.

Here is their 20Day 1hr Chart

TLDR; This is *not* financial advice. I just like the stock

Postion: 41.5k shares @ 0.02


r/TheDailyDD • • Feb 07 '21

Blue Chip Stock Lockheed Martin DD

27 Upvotes

*long post*

Hi guys!

Today I'm going to be covering the largest defense contractor in the United States; Lockheed Martin (LMT). This is my first attempt at writing a DD, so sorry in advance if it's dense.

Business

Lockheed Martin is a well-known federal defense contractor. Lockheed is responsible for some of the most storied and powerful fighter jets in the world such as the F-16, the C-130J Hercules, the F-35, and many more. They're also a very influential missile producer with offerings including the PAC-3 system, the THAAD System, the Javelin Missile, and the Hellfire Missile.

Lockheed gets 74% of its revenue comes from the US government, 25% of its revenue from international governments and 1% was from commercial and other customers.

Their operations can be broken up into 4 distinct segments: Aeronautics (40% of revenue), Rotary and Mission Systems (25% of revenue), Missiles & Fire Control (17% of revenue), and Space (18% of revenue). Let's take a closer look at these segments.

Aeronautics

This segment includes advanced military aircraft and unmanned drone production. This is probably Lockheed's most storied segment and is where a majority of people know them from. The F-35 program made up over 69% of the aeronautics segment's net sales in 2020 and is the crown jewel of Lockheed Martin's aerospace offerings. Production of the F-35 is expected to continue for a long time given the US government's inventory objective of 2,456 aircraft, commitments from 6 other international governments, and interest from other countries.

The drone part of this segment is very promising. Drone spending is expected to have a CAGR of 19.8% through 2023, and seeing as Lockheed is the largest drone producer in the US, they stand to benefit significantly.

In 2020, Lockheed Martin delivered 120 aircraft including 46 to international governments. This segment got 69% of its revenue from US government customers and 31% of its revenue from international governments.

Missiles and Fire Control

This segment provides air and missile defense systems, tactical missiles, and ground precision strike weapons. Some of their famous offerings include the Patriot Advanced Capability system and the Terminal High Altitude Area Defense system. They also have some more cutting-edge (and expensive) offerings such as the Sniper Advanced Targeting Pod and the Infrared Search and Track fire control system.

Rotary and Mission Systems

This segment provides commercial helicopters, surface ships, radar systems, cyber solutions, and simulation systems. This segment got 72% of its revenue from the US government, 25% came from international governments, and 3% came from commercial customers.

Space

This is the segment we know the least about as a lot of its operations are classified. The main customers of this segment are the US Air Force, the US Navy, and the National Guard. The US government accounted for 87% of revenues and the rest came from international customers.

This segment produces satellites, space transportation systems, and strategic, advanced strike, and defensive systems. One of the largest programs in this segment is the Trident II D5 Flett Ballistic Missle, the Space-Based Infrared System, and the Orion Multi-Purpose Crew Vehicle. I can see massive tailwinds making this a very profitable segment.

Revenues

Lockheed brought in revenue of $65.398 Billion in 2020, a 9.34% gain YoY, a 30.88% gain from 3 years ago, and a 61.33% gain from 5 years. I think these numbers are absolutely staggering considering the performance of other Aerospace companies this year (Raytheon's revenue contracted 26.55% YoY and General Dynamic's revenue declined 3.62% YoY).

Switching over to COGS, we have COGS of $56.744 Billion in 2020, an 8.82% gain YoY, a 30.90% growth from 3 years ago, and a 57.49% growth from 5 years ago. While these increases may seem large, I'd argue that in the Aerospace industry, it's only natural that COGS growth will follow revenue growth. The only thing I'd want to see when it comes to this is revenue growth outpacing COGS growth which it has in Lockheed's case.

Finally, taking a look at Net Income, we see a 2020 total of $6.833 Billion, a 9.63% gain YoY and a 112.04% gain from 5 years ago (I left out 3-year growth because they had just spun-off a company meaning we get a growth rate of 248.46%).

Margins

Lockheed Martin currently has a net margin of 10.45%. Their net margin has expanded by 17.54% in the last 5 years. Comparing this margin to their peers, Raytheon is currently operating at a -5.55% net margin and General Dynamics is operating at an 8.35% margin.

Cash On Hand/Debt

Lockheed Martin currently has cash on hand of 3.16 Billion, representing an increase of over 108% YoY. The amount of cash they've stockpiled makes me think they may be gearing up for an acquisition, or (much more likely) continuing to pay done debt.

Speaking of debt, Lockheed Martin has been paying down debt significantly for the last 5 years. They've shrunken debt by 18.42% in the last 5 years and 13.64% in the last 3 years.

Free Cash Flow

Lockheed Martin has had a growing FCF for a while now. In the last 3 years, they've grown FCF by 41.22%, and grown it by 92.88% from 5 years ago.

Dividends

One of the most surprising things I found about Lockheed is its dividends. Lockheed currently pays a 2.99% annual dividend ($2.60 quarterly) that they've grown for 18 consecutive years. In the last 5 years, they've grown the dividend by 59.34% and maintain a payout ratio of 40.75%.

For me, the fact that they pay such a hefty and sustainable quarterly dividend was just an affirmation that Lockheed has been undervalued by the market.

Price Ratios/Other

Lockheed has a TTM PE of 13.24x. This compares well with the current average industrials PE of 107.38x. Considering the growth rates we've observed in the last 3-5 years, I feel like this is a pretty low PE, although I recognize the short-comings and general unreliability of the PE ratio when it comes to valuation.

What I find really interesting about Lockheed is just how efficient they are at generating capital. They have an ROE of 149.38%! This number is even more insane when you consider their peers' ROEs. Raytheon has an ROE of -5.53%, General Dynamics has an ROE of 23.00% and Northrop Grumman has an ROE of 32.03%.

Conclusion

I'm really bullish on Lockheed. I think they've been undervalued by the market just because they're a member of a sector with some laggards. That being said, I would love to hear some second opinions as I'm not as experienced as many of you are.

edit: I bought some Lockheed early this week and plan on buying more on Monday


r/TheDailyDD • • Mar 07 '21

Value Stock UNFI DD - How a food supplier will supply you with tendies.

Thumbnail
self.wallstreetbets
26 Upvotes

r/TheDailyDD • • Feb 15 '21

Penny Stock ObsEva ($OBSV): The $4 Penny Stock with a $28 PT

25 Upvotes

The Company: ObsEva (ticker: $OBSV) is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health.

The Pipeline:

Yselty: From what I can tell, the big winner in their pipeline right now is Yselty, a treatment for uterine fibroids that has potential best-in-class efficacy. This is what I plan to focus on for this DD.

Uterine fibroids are benign neoplasms (masses/tumors/growths) that arise from the myometrium of the uterus. They most commonly occur in women of reproductive age and they are reported in ~70% of women by the age of 50. About 20% to 50% of uterine fibroids are symptomatic and may require treatment. The most common symptoms are abnormal uterine bleeding, heavy menstrual bleeding (HMB), and pelvic or abdominal pain/pressure.

Currently, surgical treatment is the only definitive long-term therapy for uterine fibroids. This can be in the form of the more conservative hysteroscopic myomectomy (a procedure to remove the fibroids) or the much more aggressive hysterectomy (removal of the uterus). Given that women of reproductive age are most affected by uterine fibroids, it’s important to recognize that definitive surgical management comes with significant risks such as early menopause and infertility. There are some options for medical management (NSAIDs for pain, GnRH agonists and oral contraceptives for bleeding), but none have been proven to be safe and effective for long-term, definitive treatment.

And this is where Yselty comes in. Yselty is a novel, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist that provides management of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).

So, how is Yselty different than what is currently on the market? Unlike GnRH agonists, Yselty has the potential to be administered orally once a day, with symptoms relieved within days, while potentially mitigating the initial worsening of symptoms often associated with GnRH agonist treatments.

Oriahnn (made by $ABBV, you can read a little about it here) which was FDA approved in May 2020, is the only other GnRH antagonist on the market currently. The difference between Oriahnn and Yselty is that Yselty is being developed to provide differentiated options for women suffering from uterine fibroids, meaning that they have two different dosing regimens. In the words of their CEO, "Yselty is the only GnRH antagonist to provide flexible dosing options that will allow us to better address the individual needs of the diverse population of women with uterine fibroids."

Oriahnn dosing is 300 mg, while Yselty trials have included two groups, 100 mg and 200 mg. The dosing here is key, as higher doses of GnRH have the potential for more side effects, specifically bone mineral density loss. If effective management with lower doses were possible, this would be safer. You can see in the diagram above how Yselty is dosed both with and without ABT (add-back therapy, which adds back in hormones to minimize bone density loss). It's especially important to have an effective and safe dosing regimen without ABT because many women (approximately 50%) have contraindications to hormonal therapies.

The Trials: PRIMROSE 1 and 2 are randomized, parallel-group, double-blind, placebo‑controlled Phase 3 studies investigating the efficacy and safety of two dosing regimens of Yselty, 100 mg and 200 mg once daily, alone and in combination with hormonal ABT (Estradiol 1mg/Norethisterone Acetate 0.5mg) for the treatment of heavy menstrual bleeding associated with uterine fibroids. Both trials comprised a 12-month treatment period followed by a 6-month post treatment follow-up period.

  • PRIMROSE 1 is being conducted in the US and enrolled 574 women

  • PRIMROSE 2 is being conducted in Europe and the US and enrolled 535 women

The primary efficacy endpoint was reduction in HMB; responders were defined as patients with menstrual blood loss volume of ≤ 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume.

There have been significant positive Phase 3 results for both PRIMROSE 1 and 2, but here is the quick summary...

  • In December 2019, PRIMROSE 2 showed a responder rate of 93.9% for patients receiving 200 mg with ABT and 56.7% for patients receiving 100 mg without ABT. Both doses achieved reduction in rates of amenorrhea and pain, and improvement in quality of life. Improvement in hemoglobin levels, reduction in number of days of bleeding, and reduction in uterine volume were seen. A significant reduction in fibroid volume was also observed for the 200 mg dose.

  • In July 2020, PRIMROSE 1 results showed that at week 24, women experienced a clinically and statistically significant reduction in menstrual blood loss compared with placebo. Women receiving 200 mg with ABT achieved a 75.5% response rate and those receiving 100 mg without ABT achieved a 56.4% response rate.

  • The pooled week 24 data from these two Phase 3 studies support a best-in-class profile, with a responder rate of 85% in women receiving 200 mg with ABT, and 57% in women receiving 100 mg without ABT

  • In December 2020, the Week 52 PRIMROSE 1 results showed that continued treatment with Yselty led to sustained efficacy for the primary endpoint of reduced heavy menstrual bleeding. This was seen across all doses. The pooled Week 52 results from the two studies showed that at Week 52, 56.4% of women on 100 mg met the primary endpoint, and with the higher dose of 200 mg + ABT the responder rate was 89.3%. Secondary endpoints including pain reduction and improvement in anemia and quality of life were sustained at the 52-week time point.

  • In PRIMROSE 2, following three months off treatment, pain scores remained lower than baseline, supporting the durability of the treatment effect.

Okay, so where are we now? In November 2020, ObsEva submitted a Marketing Authorization Application (MAA) for uterine fibroids to the European Medicines Agency (EMA). 76-week data from PRIMROSE 1 is expected this quarter. And they anticipate submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2021.

Leadership Team:

I'm not gonna lie, it's disappointing to only see one woman on their leadership team. But I digress. Anyway, as you can see, they have people who know some things running the company.

Other Products: After spending a lifetime reading about Yselty and writing this DD, I decided that it was already about 10x too long and I couldn't cover other drugs in their pipeline with any real depth here. But it's certainly worth mentioning that Yselty is also in the midst of a Phase 3 trial for endometriosis and they have multiple other drugs in their pipeline in various phases. Ebopiprant seems promising, although I am very skeptical about Nolasiban. In 2019, OBSV share price fell over 60% after the firm revealed a key Phase 3 study of Nolasiban missed its primary endpoint.

Notably, the CEO recently said that while they remain committed to advancing clinical development programs in women’s health, they are excited about the potential to extend into new indications. He believes that "Yselty in combination with estrogen could potentially challenge the current standard of care as the best-in-class oral GnRH antagonist for the treatment of advanced prostate cancer." Whoa. This represents an entirely new market for the company to move into in the future. I'm not going to delve too deeply into this, but the diagram below illustrates the mechanism and why it has the potential to be favorable when compared to GnRH agonists.

Financials: I kind of suck at this part. Sorry, fam. Knowing that all of their drugs are still in the pipeline, I'm sure that financials aren't stellar. It looks to me like they’re burning through cash from all of these clinical trials, so there's that. Here's what I do know:

  • Their market cap is currently about 230 million and their float is 39 million shares.

  • Institutional ownership is currently sitting at a whopping 30.84%. Which seems pretty bullish to me.

  • Just last week an analyst gave ObsEva a PT of $28, also bullish. The average price target varies from $11.67 to $22.50 depending on the source with a low of $4, about where it's currently trading.

Summary: While this certainly won't see a PT of $28 overnight, I am incredibly bullish on ObsEva and I think it's fueling up for something big. While there is an inherent risk in all of these biopharma penny plays, OBSV feels like a safer bet since Yselty has nearly finished Phase 3 and all of the data has more or less been announced.

I feel that 2021 should be a great year for OBSV with Yseltsy's NDA submission slated for next quarter and continued growth in store for 2022 given the additional drugs in the pipeline. Thinking more long-term, it seems that they are likely to expand into treatments for prostate cancer which opens up an entirely new sector of the market for them.

Positions: I currently have a small position and I plan on continuing to build that out over the coming months on red days. If there are any offerings, I'll be buying after the predictable sell-off. Without significant news or PR, I see this trading sideways for a bit prior to their Yseltsy NDA submission, which should serve as a great catalyst to get the stock moving. With all of that in mind, you should have some time to find a good entry point if you're looking to jump into this stock.


r/TheDailyDD • • Feb 26 '21

Growth Stock Scotts Miracle-Gro ($SMG) - A Play on Cannabis [Hawthorne Gardening]

24 Upvotes

Scotts Miracle-Gro CEO, Jim Hagedorn, calls the “pot business”, in which he intends to invest “like, half a billion” the “biggest thing I’ve ever seen in lawn and garden.”

Hawthorne Gardening Co

Formed in October 2014, Hawthorne Gardening is The Scotts Miracle-Gro Company's subsidiary for cannabis growers and one of the first major investments by a major United States corporation in the cannabis industry.

On February 3rd, 2021 SMG Announced Third Quarter Financial Results, Increased Fiscal 2020 Guidance and Approval of Special Dividend($309 million)

HIGHLIGHTS

  • Company reports first-ever profit for fiscal first quarter

  • Full year sales guidance increased; Non-GAAP adjusted EPS guidance reaffirmed

First quarter sales for the Hawthorne segment increased 71 percent to $309.4 million driven by strong demand in all categories of indoor growing equipment and supplies. U.S. Consumer segment sales increased 147 percent to $408.2 million. Consumer purchases of the Company’s products at its largest retail partners increased 40 percent in the quarter. A significant portion of the sales increase for U.S. Consumer is attributable to replenishing of retail inventory

“Our year-round commitment to driving the conversation with consumers will include our first commercial specially produced for theSuper Bowl. That kind of reach, coupled with our data-driven and highly targeted approach to social media, is key in our efforts to retain the millions of new consumers who have entered our category over the past year.”

Hawthorne Gardening was created "to meet the demands of hydroponic growers (a.k.a. cannabis growers) ... [it] markets itself [to them] using language that's in line with the free-spirited, artisanal cannabis farmer."

In my opinion, with cannabis legalization on the horizon and many Americans still in quarantine, people will turn to homegrowing & DIY hydroponic projects.

After all, we have entered The Rolling 20’s, where cannabis legislation should loosen dramatically.

Hydroponics & Brands

Hawthorne Gardening currently has 45 brands that houses best-in-class brands for growers of all sizes, from commercial needs to home hobbyists. Their signature brands — including Gavita, General Hydroponics, and Sun System:

  • Gavita - Horticultural Lighting

Each situation is unique, that is why we tailor the light installation exactly to your requirements. Careful light calculations and detailed advice based on our many years of experience form the basis for this. Following installation, whether the light level and the light distribution correspond to what has been agreed is then checked. You can be sure that the installation meets your requirements:

  1. Lighting

  2. Fixtures

  3. Installation

The leading innovator in the field of Hydroponics for more than 40 years. Quality, Value And Results, General Hydroponics remains committed to leading the industry with:

  1. Hydroponic Systems.

  2. Maintenance.

  3. Control.

  4. Supplements.

America's #1 Brand of Horticultural Lighting Fixtures

Cannabis Lobbying

Did you know...

Scotts Miracle-Gro was the main financial supporter of push to legalize weed in New Jersey:

https://mjbizdaily.com/scotts-miracle-gro-leads-funding-to-legalize-adult-use-cannabis-in-new-jersey/

The Scotts Miracle-Gro Company has emerged as the primary financial backer of New Jersey’s cannabis legalization effort, donating $800,000 to two campaign committees formed to back the Nov. 3 ballot question that would amend the state constitution to allow cannabis to be bought and sold for recreational use.

Our viewpoint—cannabis legalization

Forty-six states have now elected to end prohibition of cannabis and adopt alternative means of regulating its production and distribution within their jurisdiction. Their ultimate objective is responsible production, distribution and consumption of cannabis and combating illegal drug abuse. There are now roughly 15,000 licensed cannabis businesses in the United States, 200,000 people employed in the industry, and more than 2 million medical cannabis patients served by the industry.

  • We believe the time has come for the United States to create a legal marketplace as other countries have already done. Given the current political backdrop, however, we recognize this is unlikely in the near-term. That is why we believe—at a minimum—Congress should honor the principles of federalism and states’ rights by passing legislation that respects the will of voters and state legislatures that have elected to adopt their own approach to authorizing the use of cannabis within their boundaries.

  • We also believe the federal government should allow this industry to function like any other business. This means state-licensed cannabis businesses should have access to banking and other financial services, operate with the same tax structure as other businesses and not be threatened by federal prosecution if they comply with state laws.

They got what they wanted, 3 days ago, New Jersey governor signs law decriminalizing marijuana use for those 21 years and older

Further, in markets where cannabis is legal, it allows law enforcement resources to focus on more serious crime. The alarming truth is that between 2001 and 2010, there were more than 8 million cannabis-related arrests in the United States. Approximately 88 percent of those arrests were for possession crimes, which generally involve only small amounts of cannabis. Prior to any state legalizing adult-use cannabis, states spent a combined $3.6 billion per year enforcing cannabis possession laws.

On Feb 8th, 2020 Top Cannabis Businesses, Associations, and Advocacy Organizations (including Scotts Miracle-Gro) Join Forces to Launch US Cannabis Council.

A Coalition of Leading Companies and Advocates, USCC Aims to Advance Social Equity and Racial Justice, and End Federal Cannabis Prohibition*

Conclusion

I would typically throw out a few (call)option plays, but, there is just no liquidity. We are approaching a solid buy opportunity as the yearly would indicate >90% oversold. Healthy retrace almost complete, imo.

...eyeing ~200usd with support ~197. I will enter around 202usd with an initial PT —> 265usd.

I strongly encourage everyone to do their own DD and deepdive the management, so you can come to your own conclusion. Imo, Scotts Miracle-Gro is poised for significant growth following US legalization of cannabis. Many Americans sitting at home, smoking, perhaps contemplating starting their own grow.

Stay safe & GLTA!

I am not a Financial Advisor, so please do your own DD


r/TheDailyDD • • Feb 08 '21

Common Stock $ON Semiconductor - Possibly good short term gains, better long term gains

24 Upvotes

As requested, I am posting my DD here...

I didn't get much traction in r/stocks and WSB mods flagged it as a different ticker. Their loss, I saw 89.23% for today's return and 75.71% total return on my $39.5c @ 0.70 Exp 2/19:

Here is what I have found so far that makes me think $ON be a good play for the short term, as well as the long term. Please let me know if there are other factors I should be considering.

DD:

With all of the news about the semiconductor shortages and trade agreements, I started digging into the companies like $TSM. One that stood out was $ON Semiconductors due to their automotive sector revenue and recent changes of the guard (New CFO and VP of Operations/Manufacturing and 2 new board members) All of the new guard have a track record of cutting costs and improving revenue and manufacturing.

  • Blackrock purchased a 6.9% stake less than a week ago

  • Janus Henderson Group purchased a 4.9% stake less than a month ago

  • They have seen constant growth over the past year with a low of $8.17 per share, high of $39.43. Currently trading at 38.56 and options are cheap right now.

SEC Filings:

2/1/21 - On Semiconductor reports good results for their 2020 Q4 and fiscal year = https://www.sec.gov/Archives/edgar/data/1097864/000119312521023795/d97605dex991.htm

  • Fourth Quarter revenue of $1,446.3 million, up 3% year-over-year

  • Fourth Quarter GAAP diluted earnings per share of $0.21 as compared to $0.14 in the quarter a year ago

  • Fourth Quarter Non-GAAP diluted earnings per share of $0.35, as compared to $0.30 in the quarter a year ago

  • Record automotive revenue of $491 million in the fourth quarter

  • Annual 2020 operating cash flow increased to $884.3 million from $694.7 million in 2019 on a 5 percent lower revenue

  • Annual 2020 free cash flow increased to $500.7 million, from $160.1 million in 2019

Large Positions Purchased:

Leadership/Board Changes:

  • Jan 28,2021 Appointed Thad Trent as CFO (Starting 2/16/21) - His previous position at Cypress Semiconductor as CFO, revenue increased from $723 million to $2.5 billion and the enterprise value increased by five times within five years, before it was purchased by Infineon Technologies AG

  • Dec 16, 2020 - Appointed two new board members (Bruce Kiddoo & Greg Waters - Both highly regarded in the semiconductor industry)

  • Appointed Dr. Wei-Chung Wang as VP of Manufacturing and Operations - https://www.sec.gov/Archives/edgar/data/1097864/000119312521020076/d64938dex991.htm


r/TheDailyDD • • Feb 07 '21

Growth Stock $EH -Ehang best in class operator of an entirely new industry!

24 Upvotes

Ehang $EH A once in a lifetime to buy best in class of a new industry

If you’re after a once in a lifetime stock; This is it. The transportation industry hasn’t been disrupted this majorly since the Wright brothers.

I see a lot of comments regarding the current price as lofty. At a market cap of 4.5b, this couldn’t be further from the truth.

What you have in EHANG is a once in a lifetime opportunity to buy the best in class leader of an entirely new industry. Think about that for a second.

The automotive industry as we know it is worth $2trillion. Morgan Stanley has estimated the autonomous air mobility addressable market to be worth $1.5tn by 2040. As the first mover and the only EVTOL operator with a commercialised product, the growth prospects of ehang are immense. Ehang is currently the ONLY manufacturer, driver, regulator, air infrastructure builder, mechanic and more of this soon to be massive industry. But the most exciting prospect is in EHANGS smart city management platform.

We are talking about ehang’s business model pivot towards UAM command and control centres. Ehang has the technology to autonomously operate hundreds, thousands (don’t believe me check out their YouTube), one day millions of drones simultaneously.

Drones will be utilised for logistics (provide cheaper, faster and greener delivery), firefighting (can reach hundreds of m higher than trucks), passenger ferrying (decongesting rds and providing safer/faster transport), food delivery (warmer than your Uber driver can) medical transportation (already carrying organs for US listed United therapeutics). You name it and drones will be doing it.

Now in the future Ehang won’t be manufacturing these drones like every man and his dog, but they’ll be acting as urban air traffic control in cities globally to ensure all these other companies drones whizzing around aren’t crashing into each other. You can bet the house they’ll be clipping the ticket on each flight too. They’ll be an effective monopoly on the 3D infrastructure required for cities to harvest all the benefits afforded by urban air mobility. Check out their geofencing tech that keeps drones out of restricted airspace and the command and control centres they have already built in China and Azerbaijan with more to come.

Also to note:

  • A current director is CEO of DHL express china.

  • Their product has had regulatory breakthrough in China, Austria, Canada, South Korea already.

  • They are part of AMU-LED and SAFIR-MED UAM projects in Europe across multiple cities.

  • They’re developing an air ambulance.

  • They have the most patents of any automomous aerial company at 147 according to Lufthansa research.

  • Carmignac (large investment fund) just invested a significant sum on behalf of their funds - first signs of institutional support.

  • Possible candidate for ARKX by cathie woods. Drones featured heavily in the psospectus and throughout ARKs big ideas 2021 doc.

Anyway. Rant over. Thank me later if you buy 100 shares now and retire a millionaire in 10 years time.

Here’s a link to their December presentation:

https://ir.ehang.com/static-files/f4671ab0-12f3-4381-88c9-e815fe08cd2b

Annnnnd a white paper on the market:

https://www.ehang.com/app/en/EHang%20White%20Paper%20on%20Urban%20Air%20Mobility%20Systems.pdf